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L1CAM L1-cell adhesion molecule
LC-MS/MS liquid chromatography-tandem mass spectrometry
LNA fluorescein-labelled locked nucleic acid 
LSD1 lysine-specific demethylase 1
MAd-CAM-1 mucosal vascular addressin cell adhesion molecule-1
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mRNA messenger-RNA
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NF-κB nuclear factor-κB
NIH U.S. National Institutes of Health
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PRKCQ protein kinase c theta
PRMT5 protein arginine methyltransferase 5
PROTAC proteolysis targeting chimeras
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SDH succinate dehydrogenase
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SNAI1 snail family transcriptional repressor 1
SNAI2 snail family transcriptional repressor 2
siRNA small interfering RNA 
SRD serine rich domain
SSG Scandinavian Sarcoma Group
Suv39H1 suppressor of variegation 3-9 homolog 1
TBP TATA-binding protein
TNF-α tumor necrosis factor-α
TGF-β transforming growth factor-β
TMA tissue microarray 
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9ABSTRACT
Background: Gastrointestinal stromal tumor (GIST) is one of the most common types of soft tissue 
sarcoma. The molecular mechanisms of GISTs are incompletely understood though the importance 
of KIT or platelet-derived growth factor α (PDGFRA) signaling in GIST is evident. The molecular 
mechanisms beyond KIT and PDGFRA signaling are incompletely understood. Tyrosine kinase 
inhibitors and especially imatinib, an inhibitor of KIT, PDGFRA and BCL-ABL, revolutionized the 
systemic treatment of GIST. However, advanced GISTs usually eventually progress on tyrosine 
kinase inhibitors, often because of secondary KIT mutations. There is a need for novel effective agents 
for the treatment of patients with GIST.
Experimental design: The GIST gene expression profile was investigated in an in silico 
transcriptome database comprising of human tissue and cancer samples. Two GIST cell lines were 
screened for sensitivity to 217 anti-cancer compounds. SLUG, ITGA4, PDE3A and PDE3B 
expression was studied using immunohistochemistry on tissue microarrays (TMA). We used three 
different clinical cancer patient series: the first was a series that consisted of samples from 630 tumors
from the archives of the Department of Pathology, Helsinki University Hospital; the second was a 
population-based cohort consisting of GIST patients who were treated with surgery in Western 
Sweden from 1983 through 2000; and the third series consisted of high risk GIST patients who were 
entered to the Scandinavian Sarcoma Group (SSG) XVIII/Arbeitsgemeinschaft Internistische 
Onkologie (AIO) adjuvant trial. The effects of SLUG, ITGA4 and PDE3 knockdown and selective 
ITGA4 and PDE3 inhibitors were investigated in three GIST cells lines. The efficacy of a PDE3 
inhibitor, anagrelide, was investigated in patient-derived xenograft mouse models.  
Results: SLUG was expressed in 25.0 %, ITGA4 in 52.3 %, PDE3A in 90.9 % and PDE3B in 60.0
% of the GISTs investigated. Expression of these proteins were also detected in some other human 
tumor types, but usually much less frequently. SLUG and ITGA4 expression were associated several 
factors linked with unfavorable prognosis. SLUG expression was associated significantly also with 
unfavorable recurrence-free survival both when the patients were treated with surgery alone and when 
treated with surgery followed by adjuvant imatinib. ITGA4 expression was associated with 
unfavorable GIST-specific survival and overall survival in a patient population treated with surgery 
alone. PDE3A and PDE3B expression had no significant associations with the clinicopathological 
factors studied, RFS or overall survival. SLUG and PDE3 downregulation inhibited cell proliferation 
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and induced apoptosis in GIST cell lines, whereas ITGA4 inhibition decreased GIST cell invasion. 
Anagrelide reduced or stabilized tumor growth in several GIST xenograft mouse models.
Conclusions: SLUG, ITGA4 and PDE3s are frequently expressed in GISTs. They are likely 
important factors in the molecular pathogenesis of GIST, and may influence their clinical behavior. 
As ITGA4 and PDE3s can be targeted with specific inhibitors, they could potentially be therapeutic 
targets in GIST. SLUG may mediate pro-survival signaling in GIST. Some PDE3 inhibitors, such as 
anagrelide, warrant more study as potential therapeutic agents in GIST
11
INTRODUCTION
Gastrointestinal stromal tumor (GIST) is one the most common types of sarcoma, affecting 10 to 15 
people per million per year (Soreide et al. 2016).  GIST can arise anywhere along the gastrointestinal 
tract, but is found most often in the stomach or the small bowel (Guller et al. 2015). GISTs respond 
poorly to standard cytotoxic chemotherapy and were a particularly challenging type of cancer to treat
until the year 2000, when the first patient with metastatic GIST was treated with imatinib with a
dramatic response (Joensuu et al. 2001).
Approximately 75% of GISTs harbor an activating mutation of the KIT receptor tyrosine kinase, and 
one third of GISTs that lack KIT mutation contain a mutation in the platelet-derived growth factor 
receptor α (PDGFRA) gene (Heinrich et al. 2003, Joensuu et al. 2015). Imatinib mesylate that targets 
KIT and PDGFRA is the established adjuvant therapy for patients whose tumor is considered to have 
a high risk for recurrence after surgery, and the standard first-line therapy for patients with metastatic 
GIST (Demetri et al. 2002, Joensuu et al. 2016). However, drug resistance frequently emerges when 
patients with advanced GIST are treated with tyrosine kinase inhibitors (Heinrich et al. 2006).
Although KIT and PDGFRA mutations are likely of key importance in the molecular pathogenesis of 
GISTs, identical single KIT or PDGFRA mutations are often associated with widely different GIST 
patient survival outcomes and tumor mitotic counts (Joensuu et al. 2015). Therefore, aberrations in 
several other genes may be crucially important in determining the function of GIST cells. For 
example, the transcription factor ETV1 expression has demonstrated to cooperate with KIT activation 
and the forkhead family member FOXF1 directly controls the transcription of both ETV1 and KIT
(Chi et al. 2010, Ran et al. 2017).
Despite the great success of imatinib in the treatment of GIST, several other kinase inhibitors have 
been associated with only modest further clinical benefit in the metastatic setting. Ongoing clinical 
trials are focused on tyrosine kinase inhibitors, and there is a lack of molecules that could be novel 
targets for GIST therapy.
The aim of the present study was to investigate the clinical significance of the zinc finger protein 
SNAI2 (SLUG), integrin alpha 4 (ITGA4) and phosphodiesterase 3A and 3B (PDE3A and PDE3B)
in GIST. In addition, we wanted to investigate the effects of inhibition of PDE3 on GIST cell lines
12
and xenografts, and to study whether these proteins could be a potential therapeutic target in the 
treatment of GIST.
13
REVIEW OF THE LITERATURE
1. Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the 
gastrointestinal tract. These tumors were formerly classified as leiomyomas, leiomyosarcomas or 
leiomyoblastomas, but are now recognized as a separate tumor entity (Fletcher et al. 2002). The term 
“stromal tumor” was first introduced in 1983, when Mazur and Clark discovered neoplasms that 
lacked the immunophenotypic features of smooth-muscle differentiation or Schwann cells (Mazur 
and Clark. 1983). In the mid-1990s, researchers noted that there are clear similarities between GIST 
cells and the interstitial cells of Cajal, which serve as pacemakers for the peristaltic contractions of 
the gastrointestinal tract (Huizinga et al. 1995, Kindblom et al. 1998, Sircar et al. 1999). Both types 
of cells express the KIT receptor tyrosine kinase and are dependent on the stem cell factor (Huizinga 
et al. 1995). A groundbreaking finding was made in 1998 when Hirota and his colleagues reported 
that gain-of function mutations in the KIT receptor tyrosine kinase (RTK) gene are present in the 
majority of GISTs (Hirota et al. 1998).
GISTs were considered generally resistant to chemotherapy, and patients with GIST had often poor 
outcome. The new insights of the biological character of GIST, together with the introduction of 
tyrosine kinase inhibitor (TKI) treatments, increased the interest in GIST and revolutionized the 
treatment of this tumor type (Druker et al. 2001, Joensuu et al. 2001). In 2003, activating mutations 
in the platelet derived growth factor receptor alpha (PDGFRA) gene, which belongs to same family 
of receptor tyrosine kinases as KIT, were discovered in some GISTs (Heinrich et al. 2003, Hirota et 
al. 2003). Approximately 85 % of GISTs harbor an activating mutation in either KIT or PDGFRA
(Corless et al. 2004, Joensuu et al. 2015). The rest of GISTs (10-15 %) may harbor mutations in other 
genes, including SDH (succinate dehydrogenase), NF1 (neurofibromatosis type 1), BRAF or KRAS 
(Pantaleo et al. 2015).
Inhibition of KIT and PDGFRA oncoproteins with tyrosine kinase inhibitors made inoperable and 
metastatic GISTs treatable, and made GIST a model of effective targeted therapies among solid 
cancers. Despite the success of tyrosine kinase inhibitors, drug resistance frequently emerges in these 
tumors, and new therapy approaches are thus needed.
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1.1 Epidemiology
The incidence of GIST around the world is already quite well determined, even though GISTs have 
been properly recognized and diagnosed only since the late 1990s. A recent systematic review of the 
global epidemiology of GIST that included altogether 29 studies comprising more than 13,550
patients from 19 countries found the reported annual incidence of GIST varies between 4.3 and 22.0 
cases/million/year (Soreide et al. 2016). However, most of the studies report an incidence between 
10 and 15 cases per million. The studies found an increased risk and a higher incidence with 
advancing age with age-related incidence over 30 per million for patients over 70 years of age (Ma 
et al. 2015, Yan et al. 2008). The annual incidence is approximately 7,500-11,000 new cases in Europe 
and approximately 3,000-5,000 cases in the USA. 
GISTs are thus generally found in older people, and the median age at diagnosis is in the mid-60s in 
most of the population-based studies. GIST are rarely found in children and young adults (Miettinen 
et al. 2005, Prakash et al. 2005). GISTs have no clear gender distribution (Miettinen et al. 2005),
although in most series GISTs are slightly more common in males than in females. A few families 
with a germ-line KIT or PDGFRA mutation exist, but GISTs are usually sporadic (Li et al. 2005, 
Nishida et al. 1998). In addition, a few syndromes, neurofibromatosis type I, the Carney’s triad (GIST, 
extra-adrenal paraganglioma, and pulmonary chondroma without SDH-mutation), and the Carney-
Stratakis syndrome (GIST, extra-adrenal paraganglioma, and pulmonary chondroma with SDH-
mutation) are associated with frequent GIST development (Carney. 1999, Miettinen et al. 2006, Pasini 
et al. 2008).
1.2 Clinical features
GISTs can exist anywhere along the gastrointestinal tract but are found most often in the stomach 
(~55%), small intestine (~32%) or rectum (~6%), and only rarely in other locations (Soreide et al. 
2016). The majority of the GIST patients have local disease, but about 20% of GISTs are metastatic 
at the time of the diagnosis (Guller et al. 2015). Metastases occur usually in the liver or other intra-
abdominal sites, whereas metastases outside of the abdomen are uncommon (Dematteo et al. 2002, 
Nilsson et al. 2005, Zaydfudim et al. 2012). Metastases may occur up to 20 years after initial surgery
(Joensuu et al. 2012). Clinical symptoms such as abdominal pain, bleeding, anemia, fatigue, 
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dysphagia, satiety and obstruction are associated with GIST (Nilsson et al. 2005). Patients may also 
present a tumor with no symptoms. 
The median tumor size is approximately 7 cm at the time of GIST diagnosis (Guller et al. 2015).  
Almost 50 % of tumors are larger than 5 cm, and only 13 % in the < 2 cm size group (Soreide et al. 
2016). GISTs were first grouped to four NIH risk categories (very low, low, intermediate and high) 
based on tumor size and mitotic counts (Fletcher et al. 2002). Newer risk-stratification schemes for 
operable GIST are also available, based on tumor mitotic count, site, size, and presence of tumor 
rupture (Gold et al. 2009, Joensuu. 2008, Miettinen and Lasota. 2006, Rutkowski et al. 2011, Woodall 
et al. 2009). The novel prognostic heat maps and contour maps may, however, be more accurate than 
these risk-stratification schemes (Joensuu et al. 2012).
1.3 Histopathology
GISTs are usually well-circumscribed, highly vascular tumors that are surrounded by a
pseudocapsule. The radiologic and gross appearance of GISTs can, however, be highly variable. 
GISTs may have intraluminal, intramural, and external components, pedunculated extramural 
components, and cystic appearances (Miettinen and Lasota. 2013). GISTs have three principal 
cytomorphologic subtypes: 1) the spindle-shaped type (~70%) displays cells with palely eosinophilic 
fibrillary cytoplasm, ovoid nuclei, and ill-defined cell borders; 2) the epithelioid type (~20%) 
composed of round cells with eosinophilic to clear cytoplasm arranged in sheets and nests, and 3) the
mixed type (~10%) (Fletcher et al. 2002). Each subtype can have variable cellularity as well as 
sclerotic, collagenous, or myxoid stromal changes. Pleomorphic and dedifferentiated GISTs are also 
seen occasionally. Tyrosine kinase inhibitor treatments may induce dramatic changes in cellularity, 
and cause marked hyaline degeneration and other stromal alterations (Pauwels et al. 2005).
Immunohistochemical stainings are used to confirm the diagnosis of GIST. Most of the GISTs 
(~95%) stain positively for the KIT protein, and KIT is considered to a useful biomarker of GIST in 
the differential diagnosis (Nilsson et al. 2005, Sarlomo-Rikala et al. 1998). In most cases the staining 
is strong and diffuse, but the staining pattern can, however, vary from membranous and clearly
cytoplasmic to a perinuclear dot-like pattern (Miettinen and Lasota. 2013). Approximately 5% of 
GISTs are KIT-negative (Debiec-Rychter et al. 2004). Another very useful GIST biomarker, which 
is frequently expressed also in KIT-negative GISTs, is anoctamin-1 (ANO1), also known as 
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“discovered on GIST” (DOG1) (West et al. 2004). ANO1 is a calcium-activated chloride channel 
protein expressed also in the Cajal cells (Hwang et al. 2009). At least 95 % of GISTs stain positively 
for ANO1 (Miettinen et al. 2009). Together KIT and ANO1 immunostains cover nearly 100 % of 
GISTs. Other commonly expressed, but less-specific and sensitive GIST markers include CD34, 
expressed in approximately 70 % of GISTs, and protein kinase C (PKC)-theta, expressed in about 85 
% of GISTs (Miettinen et al. 2005, Motegi et al. 2005).   
1.4 Molecular biology
Oncogenic KIT and PDGFRA mutations are the main molecular drivers of GIST. Both genes map to 
chromosome 4q12 and encode a type III receptor tyrosine kinase (Stenman et al. 1989). These 
structurally related kinases contain an extracellular ligand binding region, a transmembrane section, 
a juxtamembrane domain, and cytoplasmic kinase domains, one with an ATP-binding pocket and the 
other with a kinase activation loop (Figure 1) (Hubbard. 2004, Ullrich and Schlessinger. 1990).
Normally KIT and PDGFRA are activated by binding of the stem cell factor and platelet derived 
growth factors, respectively. Binding of the ligands results to dimerization and cross-phosphorylation 
of the cytoplasmic kinase part that leads to activation of signaling routes regulating cell proliferation 
and survival (Blume-Jensen et al. 1991). KIT is also known to have a critical function in the 
development and maintenance of various cell types including the mast cell, melanocytes, 
hematopoietic cells, germ cells and the interstitial cells of Cajal (Blume-Jensen et al. 1991, Lev et al. 
1993, Maeda et al. 1992). PDGFRA has a role in gastrulation and in the development of the cranial 
and cardiac neural crest, the lungs, the skin, the gonads, the intestine, the central nervous system, and 
the skeleton (Andrae et al. 2008)
KIT and PDGFRA mutations can be found in any of the parts of the genes that encode the protein 
domains, but they are most often found in KIT exon 11 that encodes for the juxtamembrane domain 
of the KIT protein (~90 % of KIT mutations and ~65% of all GISTs). Approximately 10 % of GISTs 
have exon 9 KIT mutation, encoding for the extracellular dimerization domain. Primary KIT
mutations occur rarely (~2 %) in either exon 13 (encodes for the ATP binding pocket) or exon 17 
(kinase activation loop) (Corless et al. 2004, Heinrich et al. 2003). Constitutively activating PDGFRA
mutations are identified in approximately 10-15 % of GISTs. Unlike KIT, these mutations are usually 
found in the part of the gene that encodes the kinase activating loop (exon 18) or the ATP-binding 
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pocket (exon 14), and only relatively rarely in PDGFRA exon 12 that encodes the juxtamembrane 
domain (Joensuu et al. 2015).
KIT exon 11 mutated GISTs can occur anywhere along the gastrointestinal tract.  Exon 11 mutations 
include missense mutations, insertions, deletions and infrequently internal tandem duplications
(Fletcher and Rubin. 2007, Lasota and Miettinen. 2008). Tandem repeat mutations are associated with 
more favorable clinical outcome, whereas deletions are associated with a shorter progression-free and 
overall survival. Especially KIT exon 11 codon 557–558 deletions are associated with poor prognosis 
(Corless et al. 2011, Martin et al. 2005, Wardelmann et al. 2003), unless the patient is treated with 
adjuvant imatinib, which abolishes the adverse influence of this mutation on prognosis (Joensuu et 
al. 2017).
KIT exon 9 mutations occur most commonly in small intestinal GISTs that are frequently considered 
high-risk tumors (Antonescu et al. 2003, Miettinen et al. 2006). Most exon 9 mutations are 
characterized by a six base pair insertion introducing a tandem alanine-tyrosine pair (AY502-503)
(Lasota and Miettinen. 2008). The kinase domain of exon 9 mutant KIT is similar to the wild type 
KIT, which affects imatinib efficacy, and patients with KIT exon 9 mutation are recommended to be 
treated with a high daily dose of imatinib (Debiec-Rychter et al. 2006, Marrari et al. 2010). KIT exon 
13 and exon 17 mutations are rare in patients who have not been treated with tyrosine kinase 
inhibitors, and occur slightly more often in the small intestine GISTs as compared to other locations. 
Mutations in exon 13 and exon 17 are usually substitutions and occur often in codons 642 and 822, 
respectively (Lasota et al. 2008).
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Figure 1.  Structure of KIT and PDGFRA receptor tyrosine kinases. Adapted from Joensuu et al. 2013.  
 
Most of the PDGFRA exon 14 and exon 18 mutations are missense mutations, but include also in-
frame deletions and internal tandem duplications. Substitutions are most often found at D842 in exon 
18, and D842V is notorious for its resistance to imatinib and sunitinib (Corless et al. 2005, Hirota et 
al. 2003). The majority of GISTs with a PDGFRA mutation arise in the stomach, and they usually 
have a favorable clinical course following surgery alone (Joensuu et al. 2015).    
 
Up to about 10 % of GISTs do not have a detectable KIT or PDGFRA mutation. This GIST population 
was previously referred to as “wild-type” GIST, but is better named as “non-KIT, non-PDGFRA-
mutated” GIST, since mutations in other genes may occur in this subset of GISTs. Recent studies 
have revealed that this is a heterogeneous group of GISTs with various oncogenic mutations or gene 
silencing. BRAF exon 15 V600E mutations are identified in some “wild-type” GISTs (Agaimy et al. 
2009, Agaram et al. 2008, Hostein et al. 2010). Defects in the four genes (mutations or epigenetic 
changes) encoding for the succinate dehydrogenase (SDH) complex have been identified in the 
majority of “wild-type” GISTs (Boikos et al. 2016). SDH-deficient GISTs include especially pediatric 
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GISTs. Germline SDH mutations are associated with the development the Carney–Stratakis syndrome 
(Janeway et al. 2011). Patients with neurofibromatosis-1 have a high risk to develop a GIST. Most of 
such GISTs do not contain a KIT mutation, are located in the small-intestine and generally have 
favorable prognosis (Andersson et al. 2005, Miettinen et al. 2006).
1.5 Management of localized GIST
1.5.1. Surgery
Macroscopically complete (R0/R1) surgery is the standard treatment for localized GIST. GIST larger 
than 2 cm should be resected as well as smaller symptomatic (bleeding) GISTs (Miettinen and Lasota. 
2006).  Small to medium sized gastric GISTs are often treated with wedge resection and localized 
intestinal GISTs with segmental resection. Small and medium-sized GISTs are now increasingly often 
treated with laparoscopic surgery (Novitsky et al. 2006, Otani et al. 2006, Piessen et al. 2015). Larger 
GISTs require open surgery and more extensive resections. The aim of surgery is to achieve negative 
microscopic margins (R0). The optimal width of the tumor-free margin has not been defined, but 
there is little evidence suggesting that patients with microscopically positive margins (R1) require re-
extension (McCarter et al. 2012). Tumor rupture during surgery should be avoided, as tumor rupture
is associated with an increase of peritoneal implants and recurrence of the disease (Rutkowski and 
Ruka 2009). GIST do not usually give rise to lymph node metastases (apart from pediatric GISTs), 
and lymphadenectomy is not required. 
1.5.2. Neoadjuvant (preoperative) imatinib treatment
Preoperative imatinib therapy may be given to selected patients with locally advanced GIST.
Preoperative imatinib should be considered to shrink the tumor and allow organ sparing when up-
front surgery might lead to extensive organ resections. Neoadjuvant treatment may be beneficial for 
patients with a large or unresectable tumor or when a small GIST is difficultly positioned, notably 
rectal GISTs (Rutkowski et al. 2013). The optimal duration of preoperative imatinib is unknown, but 
it is often administered for 6 to 12 months to allow maximal tumor shrinkage. Imatinib is continued 
until surgery and should be resumed after surgery to complete 3 years of treatment when the risk of 
recurrence is substantial. Neoadjuvant imatinib is not recommended for all patients, since not all 
GISTs respond to imatinib, and estimation of the need for adjuvant therapy may be challenging or 
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not possible after neoadjuvant imatinib treatment. GIST mutation status should be evaluated routinely 
prior to starting tyrosine kinase treatment for GIST.
1.5.3. Adjuvant (post-operative) imatinib treatment
Imatinib is the only tyrosine kinase inhibitor that has been studied in adjuvant treatment setting of 
operable GIST. In two randomized trials, adjuvant imatinib administered for either 1 year or 2 years 
improved recurrence-free survival but overall survival benefit was not observed (Casali et al. 2015, 
Corless et al. 2014). In the third trial, adjuvant imatinib was found to prolong overall survival in high 
risk patients. In the Scandinavian Sarcoma Group SSGXVIII trial that compared 3 years of adjuvant 
imatinib to 1 year of imatinib in a patient population considered to have a high risk of GIST recurrence 
after surgery alone the patients treated with imatinib for 3 years survived longer (Joensuu et al. 2012, 
Joensuu et al. 2016). Based on the results of this trial, both the European Society for Medical 
Oncology (ESMO) and the U.S. National Comprehensive Cancer Network (NCCN) now recommend 
at least 3 years of adjuvant imatinib for patients who have a high risk for GIST recurrence despite 
macroscopically radical surgery (ESMO/European Sarcoma Network Working Group. 2014). Two 
randomized trials are currently evaluating a longer than the 3-year duration of imatinib as the adjuvant 
treatment of high-risk GIST. 
1.6 Management of advanced GIST and imatinib resistance
Imatinib is the standard first-line treatment for the patients with unresectable or metastatic GIST. 
Before the imatinib era, treatment of the patients with advanced GIST was ineffective. Only a
minority of GIST patients (<10 %) responded to conventional chemotherapy, and the median survival 
time for the patients with advanced disease was only about 18 months (Dematteo et al. 2002). Imatinib 
treatment improved tremendously progression-free survival and overall survival of GIST patients in 
multiple studies. Imatinib was originally introduced for the treatment of chronic myeloid leukemia 
(CML) due to its ability to inhibit the fusion oncoprotein BCR-ABL (Druker et al. 1996). ABL has 
structural similarity with KIT and several other tyrosine kinases. Imatinib binds directly to the ATP 
binding pocket of KIT inhibiting the ATP binding (Mol et al. 2004).
Imatinib was first used clinically to treat a patient with metastatic GIST, and a dramatic response was 
seen (Joensuu et al. 2001). In the following international clinical trials 70-85 % of patients with 
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advanced GIST achieved disease control and the median time to disease progression was 18-24
months (Blanke et al. 2008, Demetri et al. 2002). Currently the median survival of the imatinib-treated 
patients with advanced disease is at least 5 years, with 19-23 % or more of the patients surviving 
more than 10 years (Blanke et al. 2008, Casali et al. 2017, Heinrich et al. 2017). Of the patients with 
oligometastatic (a small number of new tumors) GIST treated with metastasis surgery and prolonged 
imatinib therapy more than 50% now become 10-year survivors, and at present a multicenter clinical 
trial is evaluation whether some of these patients are cured from overtly metastatic GIST (the STOP 
GIST trial) (Hompland et al. 2017).
KIT and PDGFRA mutation status significantly predicts for the response to imatinib therapy. Imatinib 
resistance appearing within the first 6 months of imatinib treatment is referred to as primary resistance 
(Heinrich et al. 2003). Most of the patients usually achieve a good initial response or stable disease,
but will develop tumor progression after a median of 2-3 years, referred as secondary resistance
(Casali et al. 2017). Secondary resistance is usually caused by secondary KIT or rarely PDGFRA 
mutations in the tyrosine kinase domains (Debiec-Rychter et al. 2005). Secondary mutations in KIT 
are often found in exons 13, 14, 17 or 18 (Gajiwala et al. 2009, Joensuu et al. 2015).      
Most of the GIST KIT exon 11 mutants are sensitive to imatinib, although some variants may show 
varying resistance (Lasota and Miettinen. 2008). Patients with KIT exon 11 mutation have the best 
response rates to imatinib. The median time to tumor progression is more than 1 year longer compared 
to KIT exon 9 mutants or other genomic subtypes (Debiec-Rychter et al. 2006, Heinrich et al. 2003).
Clinical objective response rates (complete or partial response) for KIT exon 11 mutant GISTs, KIT
exon 9 mutant GISTs, and “wild-type” GISTs are 64-84 %, 35-48 %, and 0-37 %, respectively 
(Heinrich et al. 2003, Martin et al. 2005, Wozniak et al. 2014). PDGFRA mutant GISTs may also 
respond to imatinib, but PDGFRA D842V is considered imatinib-resistant. The objective response 
rate for PDGFRA exon 12 mutant GIST and PDGFRA exon 18 mutant GIST are 30-100 % and 0-25
%, respectively (Heinrich et al. 2003, Martin et al. 2005, Wozniak et al. 2014).
The dose for imatinib is 400 mg per day, except for patients with KIT exon 9 mutant patients, who 
are recommended to be treated with 800 mg/day. About a third of the patients who progress on the 
400 mg dose of imatinib benefit from dose escalation to 800 mg/day (Zalcberg et al. 2005). However,
the higher imatinib dose is associated with greater toxicity, and the benefit usually lasts only for a 
few months. Patients with GIST with KIT exon 9 mutation have longer progression-free survival 
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when treated with 800 mg/day as compared with the 400 mg/day dose (Gastrointestinal Stromal 
Tumor Meta-Analysis Group (MetaGIST). 2010).
Although the majority of GIST patients with unresectable or metastatic GIST have durable response 
to imatinib, eventually most of the GISTs become resistant to imatinib. Secondary single nucleotide 
substitution mutations in KIT that encodes either the ATP binding pocket (exon 13 or exon 14) or  the 
activation loop (exon 17) are the main cause for imatinib resistance (Heinrich et al. 2006, 
Wardelmann et al. 2006). The currently approved second and third line therapy options, sunitinib and 
regorafenib, have been found to effective in randomized trials in the treatment of GIST that has 
become resistant to imatinib, but the responses are generally shorter than to first-line imatinib 
(Demetri et al. 2006, Demetri et al. 2013).  
Sunitinib is effective especially against secondary mutations located in the ATP binding pocket 
(Heinrich et al. 2008). In a randomized study sunitinib-treated patients had a longer time to tumor 
progression as compared with placebo (27.3 vs 6.4 weeks), and longer survival (Demetri et al. 2006).
In the third-line setting in a patient population whose GIST had progressed on imatinib and sunitinib, 
patients treated with regorafenib had longer progression-free survival as compared with placebo 
(median progression-free survival 4.8 vs 0.9 months) (Demetri et al. 2013).
2. Phosphodiesterases
Cyclic nucleotide phosphodiesterases (PDEs) regulate the intracellular concentrations of the cyclic 
AMP (cAMP) and cyclic GMP (cGMP) by catalyzing their hydrolysis (Beavo 1995). The cAMP and 
cGMP signaling systems regulate various biological processes in health and disease. They regulate 
cell proliferation and differentiation, inflammation, apoptosis, gene expression and metabolic 
signaling. Properties of different receptors, G proteins, cyclases and protein kinases that regulate the 
synthesis of cAMP and cGMP are well established (Conti and Beavo 2007). Eleven PDE families 
have been identified in mammalian tissues. Each of these families typically has several different 
isoforms and splice variants (Bender and Beavo 2006). These variants are unique in tissue-expression, 
gene regulation, subcellular localization and interaction with other proteins.  
PDEs have been recognized as promising drug targets in various diseases. Regulation of the 
degradation of a ligand or a second messenger often causes faster and more widespread changes in
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the intracellular concentrations of proteins as compared to regulation the rate of their synthesis, which 
makes PDEs interesting therapeutic targets. Effective PDE-based therapies are available or in the 
development for a wide range of clinical applications, including inflammatory diseases, heart failure, 
erectile dysfunction, asthma and arrhythmias (Maurice et al. 2014).  
 
2.1 Structure and function  
 
The PDEs share a similar structural organization, but have different amino-terminal regulatory 
regions, and a conserved carboxy-terminal catalytic core (Figure 2). Of the twelve PDE families 
PDE4, PDE7 and PDE8 hydrolyze only cAMP, whereas PDE5, PDE6 and PDE9 hydrolyze cGMP, 
and PDE1, PDE2, PDE3, PDE10 and PDE11 hydrolyze both (Conti and Beavo 2007, Francis et al. 
2011). The regulatory regions located in PDE N-terminal region retain structural factors that direct 
individual PDEs to various subcellular locations (Beavo 1995). The N-terminal region contains 
binding sites for ligands and allosteric effectors, dimerization domains, autoinhibitory modules, 
domains for isoform-specific protein–protein interactions and phosphorylation sites, and other 
covalent modification sites (Conti and Beavo 2007). Many cells express more than only one PDE 
family, but often in variable subcellular locations and proportions.  
 
 
Figure 2. Structure and domain organization of the mammalian phosphodiesterase families. Adapted and 
modified from Maurice et al. 2014.  
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The catalytic domains of PDEs share a similar topography that is composed of ~350 amino acids 
folded into 16 helicases (Ke and Wang. 2007). These domains contain a PDE specific, histidine 
containing motif (HD(X2) H(X4)N), and binding sites for two divalent metal ions essential for 
catalytic functions (Ke et al. 2011). Conserved catalytic domains are responsible for binding to 
cAMP, and cGMP and some phosphodiesterase inhibitors. The catalytic core contains variable 
elements regulating PDE-specific substrate and inhibitor affinity and selectivity (Keravis and Lugnier 
2012).  
Various intracellular cyclic nucleotide targets highlight also the role of PDEs in controlling of cellular 
events. Cells regulate the intracellular levels of cAMP and cGMP in a highly categorized manner and 
generate separate intracellular cyclic nucleotide pools that have different functions (Jurevicius and 
Fischmeister 1996, Stangherlin et al. 2011, Zaccolo et al. 2000). Cyclic AMP and GMP signaling 
occurs via the formation of cyclic nucleotide signalosomes. In these signalosomes the cyclic 
nucleotide effectors [protein kinase A and G (PKA and PKG), exchange factor directly activated by 
cAMP (EPAC) or cyclic nucleotide-gated ion channels] and PDEs form complexes through protein-
protein interaction with each other and/or with scaffolding proteins, such as AKAPs and RACK1 
(receptor of activated protein kinase C1) (Conti and Beavo 2007, Dodge-Kafka et al. 2005). As 
partners of signalosome complexes, PDEs modulate the diffusion and turnover of cAMP and cGMP 
gradients and regulate the diffusion of cyclic nucleotide signals into neighbor compartments (Conti 
and Beavo 2007).
PDEs integration into different signalosome complexes within various functional compartments has 
revealed the functional role of PDEs and linked them to the regulation of specific signaling pathways 
and biological responses. The expanding knowledge of PDE interactions has also opened possible 
therapeutic opportunities, but it also brings out additional challenges and questions in the 
development and design of novel therapeutics.  
2.2 Regulation of PDEs
Cyclic nucleotide signaling through G protein–coupled receptors (GPCRs) is already well 
understood, and the mechanism that control the intensity, duration, and propagation of the signals 
emanating from the receptors have been uncovered. Phosphorylation of GPCRs by PKA, PKC and G 
protein-coupled receptor kinases (GRK) causes uncoupling of the receptor from the transducer G 
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proteins and reassembly of the macromolecular complexes that control receptor signaling and 
trafficking (Perry and Lefkowitz. 2002, Reiter and Lefkowitz. 2006). Interaction of G proteins with 
the regulators of G protein signaling (RGS) and the effector adenylyl cyclases also influences AMP 
homeostasis, and each step in the cascade is regulated by many negative feedback mechanisms
(Hollinger and Hepler. 2002).   
In addition to the regulation mechanisms that control signaling from GPCR, an increase in the cell 
cAMP level invariably activates PDEs. Several PDEs are phosphorylated by PKA, including the 
PDE3 and PDE4 families. PKA-mediated activation of PDEs leads to a rapid decrease of cAMP, and 
this has been shown to be one of the major factors affecting the cell cAMP levels (Omori and Kotera. 
2007). A similar regulation operates with cGMP and PDE5. Control of the PDE5 activity occurs 
through PKG activation and cGMP binding. cGMP binding to the GAF domains of PDE5 stimulates 
phosphorylation by PKG and further increases both the affinity of the binding site in PDE5 for cGMP 
and the catalytic activity (Corbin et al. 2000, Kotera et al. 2003). Within a longer time frame, 
prolonged PKA activation causes phosphorylation of the cAMP response element-binding protein 
(CREB), which activates the transcription of PDE4 mRNAs (D'Sa et al. 2002).
The PDE1 family proteins are stimulated by Ca2+/calmodulin (CaM) binding to the N-terminal site 
of PDE1s. PKA and CaM kinase II-dependent phosphorylation reduces the binding affinity of PDE1A 
and PDE1B (Florio et al. 1994, Hashimoto et al. 1989). Ca2+/phospholipid-dependent protein kinase 
(PKC) activates PDE2A in the liver Golgi-endosomal fraction, and phosphorylation of rat PDE2A by 
the associated protein kinase inhibits PDE activity (Bentley. 2005, Geoffroy et al. 1999).
2.3 PDEs as a therapeutic target 
Mutations in the genes that encode individual PDEs, and mutations in the genes encoding proteins 
involved in the function or expression of PDEs may both be associated with several human disease. 
For example, PDE6 mutations are associated with autosomal recessive retinitis pigmentosa (Hartong 
et al. 2006), whereas PDE4 mutations correlate with ischemic stroke and schizophrenia (Fatemi et al. 
2008, Gretarsdottir et al. 2003). PDE8 and PDE11 mutations are associated with human adrenal 
adenomas and bilateral micronodular adrenal hyperplasia, respectively (Horvath et al. 2006, Horvath 
et al. 2008). Disorders in cyclic nucleotide signaling have also been shown to affect neoplasm 
formation, progression and metastases (Savai et al. 2010). Especially PDE4 and PDE5 families have 
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been evaluated as potential anticancer drug targets in experimental models. For example, inhibition 
of certain phosphodiesterases may have antitumor activity in acute myeloid leukemia and chronic 
lymphocytic leukemia (Lerner and Epstein. 2006, Ogawa et al. 2002). PDE4 inhibition suppressed 
cancer growth in a brain tumor model and in a prostate cancer xenograft mouse model (Goldhoff et 
al. 2008, Powers et al. 2015).
Many PDE-selective inhibitors have been developed, but only few have been approved for clinical 
use. This is mainly because of the off-target effects that limited their use. Although PDE-inhibitors 
predominantly inhibit specific PDE-families, and not all PDEs, they may still inhibit all family 
member proteins, often producing unwanted effects.
Most of the PDE-inhibitors have been developed against the PDE3, PDE4 and PDE5 families. PDE3 
inhibitor milrinone is approved for the treatment of acute heart failure (Movsesian and Kukreja 2011).
Cilostazol, another PDE3 inhibitor, is used to treat intermittent claudication (Dawson et al. 1998).
PDE4 inhibitors are used especially in treatment of pulmonary diseases, such as asthma, chronic 
obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis and allergic rhinitis (Rabe 
2011, Tenor et al. 2011, Torphy. 1998). Sildenafil (Viagra®; Pfizer), a PDE5 inhibitor, is the most 
well-known agent, and likely the biggest success of all PDE inhibitors. During unsuccessful clinical 
trials studying the role of sildenafil as the treatment of angina and coronary artery disease, responses 
in off target tissues were observed, and the focus of sildenafil research changed to treatment of erectile
dysfunction and later to the treatment of pulmonary hypertension (Ghofrani et al. 2006).   
2.4 The PDE3 family
PDE3 family is consist of two genes, PDE3A and PDE3B, which are able to hydrolyze both cAMP 
and cGMP. cGMP behaves also as a competitive inhibitor for cAMP hydrolysis, which is why the 
PDE3 family is called the cGMP-inhibited PDE family (Degerman et al. 1997, Maurice and Haslam. 
1990). The PDE3 family has two unique characteristics, a 44-aminoacid insert in the catalytic domain,
and the N-terminal hydrophobic membrane association domains (Degerman et al. 1997).
PDE3A has two different transcripts, PDE3A1 and PDE3A2, which encode three N-terminal variant 
forms. PDE3A1 encodes PDE3A-136 (136 kDa) with two N-terminal hydrophobic membrane-
associated regions (NHR1 and NHR2) and a catalytic domain. PDE3A-118 (118 kDa,) and PDE3A-
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94 (94 kDa) are encoded by the PDE3A2 (Wechsler et al. 2002). PDE3A is expressed in the cardiac 
tissues, smooth muscle and platelets, and is involved in the regulation of the blood pressure, cardiac 
function and oocyte meiosis and platelet aggregation (Beavo. 1995, Begum et al. 2011). PDE3B has 
only one transcript. PDE3B is expressed in cells that are important in energy homeostasis, such as 
adipocytes and hepatocytes (Beavo 1995). PDE3B is of importance especially in insulin signalling 
(Nilsson et al. 2006).
The NHR regions impact greatly the intracellular localization of the PDE3 proteins. PDE3A-136,
carrying two NHRs, is found only membrane bound, whereas PDE3A-118 containing NHR2 and 
PDE3A-94 carrying no NHR are found in both cytosolic and membrane-bound fractions (Wechsler 
et al. 2002). Both PDE3A and PDE3B with two NHRs are localized in the endoplasmic reticulum 
(Shakur et al. 2000).
PDE3s are phosphorylated at various sites on the N-terminal region by PKA, PKB and PKC 
(Degerman et al. 1997, Pozuelo Rubio et al. 2005). A few phosphorylation dependent interactions of 
PDE3A and PDE3B with the signaling regulator 14-3-3 have been described (Hunter et al. 2009, 
Onuma et al. 2002, Palmer et al. 2007, Pozuelo Rubio et al. 2005, Vandeput et al. 2013). In human 
embryonic kidney cells, PDE3A1 is phosphorylated primarily at S312 in response to PKA activation 
and PDE3A2 at S428 in response to PKC activation (Vandeput et al. 2013). Individual PDE3 isoforms 
may also integrate into different complexes in the same cell after phosphorylation. The mechanism 
of phosphorylation determines the incorporation PDE3s into different protein complexes (Ahmad et 
al. 2007, Ahmad et al. 2009, Vandeput et al. 2013).
2.5 Anagrelide
Anagrelide (6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one) (Figure 3), is a potent 
blood platelet reducing agent that is used for the treatment of essential thrombocytosis (Silverstein et 
al. 1988). Anagrelide was originally developed as an antiplatelet drug, and the thrombocytopenic 
effect was observed in preclinical studies (Abe Andes et al. 1984, Fleming and Buyniski 1979). The 
platelet-lowering effect of anagrelide results from the inhibition of megakaryocyte maturation and 
reduced proplatelet formation (Espasandin et al. 2015). Anagrelide represses GATA-1, FLI-1 and 
FOG-1, which are key megakaryocyte transcription factors and essential for the maturation and 
differentiation of megakaryocytes, suggesting that anagrelide exerts its effects upstream of GATA-1
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and FOG-1 (Ahluwalia et al. 2010, Rinaldi et al. 2008).  Gene expression studies have revealed that 
anagrelide regulates the expression of several genes. Anagrelide has been proposed to induce 
phosphorylation of eIF2a, an upstream regulator of the transcription factor ATF4, and thus increase 
the levels of ATF4 protein (Ahluwalia et al. 2015).
Figure 3. The structure of anagrelide.
Anagrelide also inhibits the function PDE3 (Gillespie. 1988). Stimulation of cAMP signaling blocks
megakaryocyte maturation and differentiation (Freson et al. 2008). Megakaryocyte inhibition by 
cAMP is mediated by PKA-dependent down-regulation of the transcription factor E2A and its target 
CDKN1A (p21) (Rubinstein et al. 2012). Anagrelide represses this regulatory E2A/p21 loop in a 
similar manner, which suggests the involvement of cAMP in anagrelide’s mechanism of action. 
However, other commercially available PDE3 inhibitors seem to have no effect on in vitro 
megakaryocyte maturation arguing against the participation of cAMP in anagrelide-induced platelet 
reduction (Wang et al. 2005). Inhibition of the platelet function is achieved at higher anagrelide 
concentrations that are required for megakaryocyte function inhibition (Espasandin et al. 2015).
Two different brands of anagrelide are available commercially. Xagrid® (Shire Pharmaceuticals) is 
used for the treatment of essential thrombocythemia. Thromboreductin® (AOP Orphan 
Pharmaceuticals AG) anagrelide hydrochloride is absorbed more slowly, which results in a lower 
maximum serum concentration (Cmax) in the plasma (Petrides et al. 2009). Anagrelide is metabolized 
into two major metabolites: 6,7-dichloro-3-hydroxy-1,5 dihydro-imidazo[2,1-b]quinazolin-2-one 
(BCH24426) that influences megakaryocytic differentiation as anagrelide, and 2-amino-5,6-dichloro-
3,4-dihydroquinazoline (RL 603) (Wang et al. 2005).
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3. Integrins 
 
The integrin receptor family was  discovered about 30 years ago, and is one of the best-understood 
cell adhesion receptors. Besides their role as major adhesion receptors, integrins have multiple roles 
also in the cell signaling and in the regulation of cell growth, survival, differentiation, division, 
migration, and apoptosis (Hynes. 2002). In tumor biology, the role of integrins in cell migration and 
invasion is probably the most studied function of integrins.  
 
Integrins consist of alpha (α) and beta (β) subunits, and in mammals 18 α and 8 β subunits form 24 
different integrins that bind to distinct subsets of the extracellular matrix (ECM) ligands (Figure 4) 
(Giancotti and Ruoslahti. 1999). Integrins mediate most of the effects of ECM through binding to 
various ECM components, organizing the cytoskeleton and activating intracellular signaling 
pathways (Hynes. 2002). Integrins transmit both chemical and mechanical signals across the plasma 
membrane in both directions (Zamir and Geiger. 2001).  
 
 
Figure 4. The integrin receptor families and their αβ associations. 18 α subunits can assort with 8 β subunits 
to form 24 distinct integrins. Adapted from Hynes, 2002. 
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3.1 Integrin functions
Clustering of integrin heterodimers into oligomers and changes in the conformation of individual 
heterodimers influence the binding of ligands (Carman and Springer 2003). Both of these are likely 
important for integrin function and their participation might vary depending on the integrin, cell type 
and biology circumstances. Integrin ectodomains can have bend “closed” conformation, intermediate 
extended conformation and extended “open” conformation (Nishida et al. 2006). These correspond 
to low affinity, activated, and activated and ligand occupied conformations on cells, respectively 
(Mould and Humphries 2004, Takagi et al. 2002). In integrin clustering the heterodimers interact with 
each other to form hetero-oligomers. This can be caused by inside-out signals that stimulate the 
recruitment of multivalent protein complexes to integrin cytoplasmic domains (Critchley and Gingras 
2008, Wu 2005) or by the release of cytoskeletal constraints leading to the free diffusion of integrins 
in the plane of the membrane (Kucik 2002).
Integrin α- and β-subunits are typical type I transmembrane proteins that have the amino terminus 
outside the cell, a single transmembrane domain and a carboxy-terminal cytoplasmic tail (Lau et al. 
2008). Integrin cytoplasmic domain interactions with each other or cytoplasmic proteins lead to 
allosteric rearrangements leading to integrin activation and inside-out signaling (O'Toole et al. 1994).
This inside-out signaling is activated especially by talin, an adaptor protein that induces a 
conformational switch in the integrin extracellular domain that leads to receptor activation and 
increased affinity for ECM ligands (Tadokoro et al. 2003). In addition to talins, kindlins also co-
activate integrins and talin-1 (Ma et al. 2008). Extracellular factors, including ECM ligands and ligand 
binding to integrins can directly activate integrins triggering the outside-in signaling (Hynes. 2002).
Inside the cell enzymes such as FAK/c-Src complex, Ras and Rho GTPases and adapters such as 
Cas/Crk and paxillin are key mediators of integrin downstream signaling. These assemble within 
dynamic adhesion structures, including focal adhesions, focal complexes and podosomes (Linder and 
Kopp. 2005, Zaidel-Bar et al. 2004).
3.2 Integrins in cancer
The role of integrins in cell migration and invasion is well established. However, integrins can also 
regulate cell proliferation (Assoian and Klein. 2008). Recent studies have illustrated the crucial, but 
at same time inconsistent, role of integrins in the regulation of tumor cell survival. In addition to their 
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ligation dependent effects, in some cases unligated integrins can also control the tumor cell survival 
positively or negatively, thereby affecting tumor metastases and growth. Besides their role in tumor 
cells, integrins on the surface of tumor-associated cells such as endothelial cells, fibroblasts and 
inflammatory cells can considerably influence the malignant behavior of the tumor (Desgrosellier 
and Cheresh. 2010).
Various integrins contribute to tumor progression. Increased expression of integrins such as αvβ3, 
αvβ5, α5β1, α6β4, α4β1 and αvβ6 correlates with disease progression in several tumor types
(Desgrosellier and Cheresh. 2010). Integrins are able to either enhance cell survival or initiate 
apoptosis, depending on the environmental state. Several mechanisms, including increased 
expression of apoptosis regulator proteins Bcl-2 and FLIP, activation of the PI3K-AKT pathway,
nuclear factor-κB (NF-κB) signaling and p53 activation, may enhance cell survival after integrin 
ligation (Aoudjit and Vuori. 2001, Aoudjit and Vuori. 2001, Bao and Stromblad. 2004, Matter and 
Ruoslahti. 2001). Depending on specific integrin-growth factor receptor pairs, these pathways are 
variably regulated. 
The role of integrins in regulating apoptosis is variable, suggesting a possible dual role for integrins 
in both promoting cell survival and inducing cell death. Some integrins such as αvβ3 and α6β4, 
enhance tumor progression while for example α5β1 inhibits oncogene-induced transformation 
(Giancotti and Ruoslahti. 1990, Petitclerc et al. 1999, Varner et al. 1995). In some mouse models of 
glioblastoma and melanoma αvβ3 integrin could inhibit tumor progression (Danen et al. 1996, 
Kanamori et al. 2004). These differences, can in some respect, be explained by the ligation status of 
integrins (Stupack et al. 2001, Zhao et al. 2005). Integrins do not function as oncogenes, because they 
lack the ability to transform cells. However, some integrins co-operate with receptor tyrosine kinases 
or oncogenes to enhance tumorigenesis. Integrin α6β4 co-operation with ERBB2 increases breast 
tumor formation and invasion, whereas integrin α1 is required for KRAS-G12D-induced lung tumor
genesis (Guo et al. 2006, Macias-Perez et al. 2008). Integrin αvβ3 might increase the tumorigenic 
potential of melanomas and various carcinomas (Huveneers et al. 2007). Integrins also seem to co-
operate with various growth factor and cytokine receptors, including epidermal growth factor (EGF) 
receptors, hepatocyte growth factor (HGF) receptors, vascular endothelial growth factor (VEGF) 
receptors and fibroblast growth factor (FGF) receptors (Bertotti et al. 2005, Byzova et al. 2000, Guo 
et al. 2006, Miyamoto et al. 1996, Nikolopoulos et al. 2004).
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3.3 Integrin alpha 4 (ITGA4)
The integrin alpha 4-chain (CD49d) associates with either the β1 chain (CD29) or the β7 chain 
forming α4β1 (very late antigen-4, VLA-4) and α4β7 (lymphocyte Peyer patch adhesion molecule, 
LPAM) integrins, respectively (Hynes. 2002). The alpha 4 integrins mediate especially cell-cell 
adhesions that are crucial to the immune function (Kinashi. 2012). They are involved in myogenesis, 
hematopoiesis, and cardiac and placental development (Arroyo et al. 1996, Rosen et al. 1992, Yang 
et al. 1995). The alpha 4 integrins are also involved in the pathogenesis of some cardiovascular 
diseases (Liu et al. 2000). α4β1 binds to the vascular cell adhesion molecule-1 (VCAM-1) that is 
expressed on the surface of endothelial and stromal cells and to fibronectin in the extracellular matrix, 
whereas α4β7 binds to the mucosal vascular addressin cell adhesion molecule-1 (MAd-CAM-1) 
(Goodman and Picard. 2012).
ITGA4 expression is dependent on the development status in the myocytes, placental and fibroblastic 
cells (Liu et al. 2000). α4 integrins have a central role in leukocyte trafficking, and they are expressed 
during hematopoiesis on early pluripotent progenitor cells, mononuclear leukocytes, and eosinophils
(Arroyo et al. 1999). These integrins are involved in the pathogenesis of several chronic diseases such 
as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases, and contact hypersensitivity
(Abraham et al. 1994, Chisholm et al. 1993, Yednock et al. 1992).
Humanized monoclonal antibody natalizumab, that targets ITGA4 has been approved for the 
treatment of multiple sclerosis and Crohn's disease by the U.S. Food and Drug Administration (FDA)
(Polman et al. 2006, Rutgeerts et al. 2009). In a xenograft model of primary leukemia, natalizumab 
prolonged survival of mice when treated with the combination of vincristine, dexamethasone, and l-
asparaginase plus natalizumab (Hsieh et al. 2013). In addition, natalizumab decreases myeloma 
growth by blocking the interaction between myeloma cells and bone marrow stromal cells (Podar et 
al. 2011).
The expression of α4β1 integrin has been associated with poor prognosis in a few cancer types 
including chronic lymphocytic leukemia and neuroblastoma (Buggins et al. 2011, Bulian et al. 2014, 
Young et al. 2015). Increased expression of α4β1 integrin has also been linked with ovarian cancer 
progression (Slack-Davis et al. 2009). Inhibition of ITGA4 in MV3 melanoma cells with heparin 
derivatives decreases melanoma metastatic potential and interaction between VCAM-1 on activated 
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endothelial and ITGA4 in melanoma cells enhances the metastatic capacity of melanoma cells
(Klemke et al. 2007, Schlesinger et al. 2012).
α4 integrins can activate critical pathways downstream of integrins, including FAK, Src, Akt and 
ERK (Wu et al. 2008). The focal adhesion kinase (FAK) is one of the key mediators of integrin 
signalling and a promoter of cell migration, and is highly expressed in malignant GISTs (Koon et al.
2004, Mitra and Schlaepfer. 2006). Interestingly, imatinib stimulated the SRC family kinase (SFK) 
and FAK activation and integrin signaling in a mouse KitV558Δ/+ GIST model (Rossi et al. 2010).
3.4 Integrins as targets for cancer therapy 
The central role of integrins in cell attachment, migration, invasion, survival and angiogenesis has
attracted attention also as a potential anticancer target. Anti-integrins are usually used in combination 
with other anticancer drugs and may have potential as imaging agents in cancer diagnosis (Cox et al. 
2010). Several synthetic peptides and humanized antibodies have been developed to interfere integrin 
functions. Even though the in vitro and preclinical results have been encouraging, the late phase 
clinical trials have, however, been mostly disappointing (Desgrosellier and Cheresh. 2010). For 
example, in a recent POSEIDON trial no improvement in efficacy was seen when treating patients 
with K-RAS wild-type metastatic colorectal cancer with an anti-av-integrin antibody (abituzumab) 
combined with the standard of care (Elez et al. 2015). Similarly, in a phase 3 trial the av-integrin 
antagonist (cilengitide) in combination with radiotherapy did not improve glioblastoma patients’
survival (Stupp et al. 2014). Integrin function complexity and integrin-growth factor receptor cross-
talk makes integrin targeting challenging, and some signaling molecules downstream of integrins 
might be more beneficial therapeutic targets. However, growing knowledge of the complex biological 
roles of integrins in cancer promotes the design of better integrin targeting agents and may improve 
the stratification of patients that are most likely to respond therapies.  
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4. The snail family of zinc-finger transcription factors
The snail superfamily is involved in enhancing of cell migration during both the embryotic 
development and tumor progression. The snail family members have also found to be important in 
the signaling cascades that affect the left-right identity, neural differentiation, cell division and cell 
survival.
The snail family members are essential for mesoderm formation in many organisms, and they are also 
involved in processes that require larger scale cell movements such as neural crest formation (Alberga 
et al. 1991, LaBonne and Bronner-Fraser. 2000, Nieto et al. 1994). The role of these transcription 
factors is of importance especially in promoting cell process that is generally known as the epithelial-
mesenchymal transition (EMT) (Batlle et al. 2000, Cano et al. 2000). In this mechanism, epithelial 
cells loose cell adhesion and polarity, may obtain migratory properties, dissociate from the epithelium 
and become mesenchymal cells.
4.1 Structure and regulation 
Snail was described first in Drosophila melanogaster, where it was shown to be essential for the 
mesoderm formation (Grau et al. 1984, Nusslein-Volhard et al. 1984). Snail was also found in 
vertebrates, including humans, and non-vertebrates like insects and nematodes (Peinado et al. 2007).
In vertebrates three snail family protein have been identified: Snail1 (Snail), Snail2 (SLUG) and 
Snail3 (SMUC). The snail family members encode zinc-finger type transcription factors. They all 
share a similar structure with a highly conserved C-terminal region containing four to six zinc-fingers,
and a more complicated N-terminal region. Zinc fingers bind to the E-box motif (5′-CANNTG-3′), 
indicating that they might compete with the basic helix-loop-helix (bHLH) transcription factors for 
the binding on the same target gene promoters (Cano et al. 2000, Kataoka et al. 2000).
The snail family members are proposed to act as transcriptional repressors on E-box binding (Batlle 
et al. 2000). The repressor activity depends not only on the finger region but also on the so called 
SNAG (Snail/Gli) domain (Grimes et al. 1996). The SNAG domain is conserved in vertebrate Snail
genes, but, for example, in Drosophila Snail does not contain the SNAG. The repressor activity in 
Drosophila is mediated through an interaction with C-terminal binding protein (P-DLS-K) (Nibu et 
al. 1998). A nuclear export sequence (NES) and a serine rich domain (SRD) in the central region of 
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Snail are important in the subcellular localization and regulation of Snail stability, respectively 
(Dominguez et al. 2003).
Snail interacts with several co-repressor complexes, such as Sin3A and the histone deacetylase 1/2 
(HDAC1/2) complex, the protein arginine methyltransferase 5 (PRMT5)/Ajuba complex, the 
polycomb repressive complex 2 (PRC2), the 14-3-3 complex, the lysine-specific demethylase 1 
(LSD1)/CoREST and the suppressor of variegation 3-9 homolog 1 (Suv39H1) complex (Dong et al. 
2013, Herranz et al. 2008, Hou et al. 2008, Hou et al. 2010, Lin et al. 2010, Peinado et al. 2004). The 
Snail activity is mainly regulated through the central part of the protein that contains most of the sites 
for post-transcriptional modification, including a serine rich domain (SRD), the nuclear export 
sequence (NES) and two lysine oxidation sites. Glycogen synthase kinase-3β (GSK-3β) is responsible 
for the phosphorylation at the SRD region, whereas the small C-terminal domain phosphatase (SCP) 
removes these phosphorylations (Wu et al. 2009, Zhou et al. 2004). The F-box/WD repeat-containing 
protein 1A (β-TrCP1) and the F-box/LRR-repeat protein 14 (FBXL14) are responsible for the 
degradation, ubiquitination and protease degradation of Snail (Vinas-Castells et al. 2010, Zhou et al. 
2004). The sequence-specific interactions with DNA are mediated via the C-terminal regions that are 
also responsible for the repressor activity of Snail. The nuclear accumulation and the repressor 
activity of Snail in the nucleus are promoted by Serine/Threonine-Protein Kinase PAK 1 
phosphorylation (Yang et al. 2005).
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Figure 5. Regulation of Snail transcription factors in epithelial-mesenchymal transition. Glycogen synthase 
kinase-3β (GSK3β) phosphorylates (P) Snail1 that facilitates the nuclear export of Snail1, and enables the 
ubiquitin (Ub)-mediated degradation of Snail1. Protein kinase D1 (PKD1) phosphorylates Snail1 that leads 
also to its nuclear export. Conversely, phosphorylation of Snail1 by p21 activated kinase 1 (PAK1) or large 
tumor suppressor 2 (LATS2), or dephosphorylation of Snail1 by small C-terminal domain phosphatase 1 
(SCP1) enhances the activity of Snail1 and promotes its nuclear retention. Snail2 is degraded by p53-mediated 
recruitment to the p53–mouse double minute 2 (MDM2) complex. Adapted from Lamouille et al. 2014.  
 
Many signaling molecules, such as the transforming growth factor-β (TGF-β), the hepatocyte growth 
factor (HGF), the fibroblast growth factor (FGF), the epidermal growth factor (EGF), the tumor 
necrosis factor-α (TNF-α), and several cytokines  may induce Snail expression in various cellular 
contexts (Nieto. 2002). FGF and EGF, for example, activate receptor tyrosine kinase (RTK) signaling 
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that eventually results in the induction of Snail (Ciruna and Rossant. 2001, Lu et al. 2003), whereas
the Nf-κB pathway regulates Snail expression through transcriptional and post-transcriptional 
mechanisms. Nf-κB binds to the Snail promoter region and increases the transcription of Snail 
(Barbera et al. 2004). Interestingly, Snail can also bind and repress its own promoter, indicating the 
existence of an autoregulatory loop (Peiro et al. 2006).
4.2 Epithelial mesenchymal transition (EMT)
In epithelial–mesenchymal transition (EMT) epithelial cells transdifferentiate into motile 
mesenchymal cells. It is essential in the fetal development, stem cell behavior, wound healing, and 
EMT contributes to cancer progression and fibrosis. Snail, the zinc-finger E-box-binding (ZEB)
transcription factor and the basic helix–loop–helix (bHLH) transcription factor are the key switches 
in cell differentiation and EMT.
In EMT, epithelial cells lose their junctions and apical-basal polarity, reorganize their cytoskeleton 
and change the signaling programs defining the cell shape and gene expression that further increases 
the motility of cells and enables the development of an invasive phenotype (Thiery et al. 2009).
Variations in EMT-associated gene expression are dependent on tissue and cell type and on the degree 
of progression towards mesenchymal differentiation. One of the hallmarks of EMT is the 
downregulation of E-cadherin (encoded by CDH1) to reinforce the destabilization of adherens 
junctions (Peinado et al. 2007). E-cadherin is considered a suppressor of invasion during cancer 
progression (Birchmeier and Behrens. 1994). In addition, the repression of genes encoding 
desmoplakin and plakophilin, and claudins and occludin stabilizes the dissolution of desmosomes and 
apical tight junctions (Huang et al. 2012). These changes prevent the reformation of epithelial cell-
cell junctions and result in the loss of the epithelial barrier function (Peinado et al. 2007).
The Snail transcription factor is one of the master regulators of the gene expression that contributes
to the repression of the epithelial phenotype and activates the mesenchymal phenotype. Of the three 
Snail proteins found in the vertebrates, Snail1 (Snail) and Snail2 (SLUG) activate the EMT during 
the fetal development, and in cancer and fibrosis (Barrallo-Gimeno and Nieto. 2005). Snail or SLUG,
by binding to the E-box DNA sequences through their carboxy-terminal zinc-finger domain, suppress 
the epithelial genes (Cano et al. 2000). In brief, upon binding to the proximal promoter region of E-
cadherin, Snail1 recruits the Polycomb repressive complex 2 (PRC2), methyltransferase G9a and 
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suppressor of variegation 3–9 homologue 1 (SUV39H1), and all of these components coordinate 
histone modifications, specifically methylation and acetylation (Dong et al. 2012, Dong et al. 2013, 
Herranz et al. 2008). In addition to suppression of epithelial genes, Snail activates genes such as ZEB 
factors, N-cadherin and matrix metalloproteinases (MMP) that contribute to the mesenchymal 
phenotype (Peinado et al. 2007).
Various signaling pathways acting through RTKs cooperate in the progression of EMT, often 
activating Snail1 expression. Snail1 and Snail2 also cooperate with other transcription regulators to 
control gene expression (Jorda et al. 2005, Vincent et al. 2009). Post-translational modifications also 
control the localization, degradation and activation of Snail (Peinado et al. 2007). GSK3β-mediated 
Snail1 phosphorylation inactivates its transcriptional activity, and several pathways including WNT 
and PI3K-AKT pathways increase Snail1 activity by influencing GSK3β-mediated phosphorylation 
(Yook et al. 2006, Zhou et al. 2004). In addition, Notch and NF-κB signaling interfere the GSK3β–
Snail1 interactions (Sahlgren et al. 2008, Wu et al. 2009).
4.3 Snail2 (SLUG)
SLUG was first identified in the neural crest and in the developing mesoderm in the chick embryos 
(Nieto et al. 1994). This translational repressor is best known to control EMT and promote cancer 
invasion and metastasis. However, SLUG has also a role in cell cycle progression (Emadi Baygi et 
al. 2010, Liu et al. 2010, Turner et al. 2006, Wang et al. 2015). SLUG is expressed in several types 
of human cancer, and its expression is often associated with various prognostic factors of unfavorable 
outcome (Cobaleda et al. 2007, Wang et al. 2013).
SLUG is expressed in migratory neural crest cells, but not in premigratory neural crest cells (Jiang et 
al. 1998). It is required for melanoblast migration and survival (Perez-Losada et al. 2002). It is also 
expressed in the developing bone, craniofacial mesenchyme, endocardial cushions and cardiac 
outflow tracts, and in the mesenchymal components of the lungs, kidneys and gut (Oram et al. 2003).
SLUG-deficient mice are viable, though they have a white forehead blaze and other pigmentation 
abnormalities in the ventral body, the tail and feet, and macrocytic anemia and infertility, indicating 
an essential role for SLUG in the hematopoietic stem cells, germ cells and melanocytes (Perez-Losada 
et al. 2002). Similarly, deletions of SLUG in the human cause the Waardenburg disease, a rare 
disorder associated with abnormal pigmentation and sensorineural deafness (Sanchez-Martin et al. 
39
2003). Interestingly, dysfunction of KIT may cause piepaldism and sensorineural deafness (Spritz 
and Beighton. 1998). Targeted SLUG deletions in mice have also phenotypic similarities with mice 
with defective KIT or stem cell factor (SCF), including abnormal pigmentation, and gonadal and 
hematopoietic defects (Motro et al. 1991, Perez-Losada et al. 2002).
The evidence for the occurrence of mesenchymal-to-epithelial transition (MET) in sarcomas has been 
obtained in several studies. SYT-SSX1 and SYT-SSX2 fusion proteins, typical for synovial sarcoma,
are able to interact with Snail or SLUG, preventing their suppressive effects on E-cadherin expression
and leading to the acquisition of epithelial features indicative of mesenchymal-to-epithelial transition
(Saito et al. 2006). SLUG has been identified as a negative regulator of E-cadherin expression in 
integrated proteomics and genomics analyses in soft tissue leiomyosarcomas. In these analyses, the 
knockdown of SLUG increased E-cadherin and decreased vimentin expression, which was associated 
with decreased cancer cell proliferation and invasion (Yang et al. 2010).
In some types of human cancer, such as lung cancer, esophageal cancer and colorectal cancer, patients 
with SLUG-positive cancer generally have poor outcome (Shioiri et al. 2006, Uchikado et al. 2005, 
Wu et al. 2015). SLUG downregulation decreases cell viability and inhibits invasiveness in preclinical 
models of prostate cancer and neuroblastoma (Emadi Baygi et al. 2010, Vitali et al. 2008). SLUG
silencing sensitizes ovarian cancer cells to cisplatin, and SLUG might have a role in the signaling 
network that drives survival and imatinib resistance of Bcr-Abl-expressing cells (Haslehurst et al. 
2012, Mancini et al. 2010).   
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AIMS OF THE STUDY
The aims of the thesis were:
1. To investigate the clinical significance of SLUG, ITGA4, PDE3A and PDE3B expression and their 
association with patient and tumor characteristics and survival in GIST.
2. To study the effects of SLUG, ITGA4 and PDE3 knockdown, and ITGA4-specific and PDE3-
specific inhibitors on GIST cell proliferation and invasion. 
3. To investigate the efficacy of a PDE3 inhibitor, anagrelide, in patient-derived GIST xenograft 
mouse models.
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MATERIALS AND METHODS
1. Patient and tumor samples (I, II, III)
The associations of GIST with potential biomarker expression, tumor features and patient survival 
outcomes were investigated in three clinical cancer patient series. The first series consisted of tissue 
samples from 630 tumors of 36 histological tumor types including samples from 55 GISTs. This 
tumor series was retrieved and identified from the archives of the Department of Pathology, Helsinki 
University Hospital. 
The second series is a population-based cohort consisting of GIST patients who were treated with 
surgery in the Western Sweden from 1983 through 2000 (Nilsson et al. 2005). Out of the total of 288 
patients in the cohort, we included in the study on SLUG 187 (64.9%) tumor tissue samples, and in 
the study on ITGA4 147 (51.0%) tumor samples. The included patients had tumor tissue available, 
tumor histology was compatible with GIST and stained positively for KIT in immunohistochemistry, 
and we also provided that the patients had information about gender, tumor diameter, and follow-up 
available. None of the patients was treated with imatinib or other tyrosine kinase inhibitors after 
surgery for GIST. 
The third series consisted of GIST patients who were entered to the Scandinavian Sarcoma Group 
(SSG) XVIII/Arbeitsgemeinschaft Internistische Onkologie (AIO) adjuvant trial (Joensuu et al. 2012, 
Joensuu et al. 2016). SSGXVIII/AIO is an open-label, multicenter, phase 3 study. The patients had 
KIT-positive, operable GIST and were at a high risk for GIST recurrence estimated according to the 
modified National Institute of Health (NIH) Criteria (Joensuu. 2008). After surgery, the patients were 
randomly allocated to receive adjuvant imatinib 400 mg per day orally either for 12 or 36 months. A 
total of 400 patients from Finland, Germany, Norway and Sweden were entered to the trial between 
February 2004 and September 2008. Representative tumor tissue for the SLUG study was available 
from 313 (85.1%) out of the 368 patients. Each patients had localized disease at the time of 
randomization. The median follow-up time after the date of randomization was 6.1 years (Joensuu et 
al. 2016).
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Institutional review committees of the Helsinki University Hospital, Helsinki, Finland, and 
Sahlgrenska University Hospital, Gothenburg, Sweden, approved the current studies on GIST 
biology. The SSGXVII/AIO trial was approved by the ethics boards of the participating hospitals and 
the national supervising authority in each country as per the national legislation.
2. Gene expression dataset (II, III)
Cancer and normal tissue mRNA expression data were derived from the MediSapiens in silico
database of human transcriptomes that contains data from almost 20,000 human genes across 9,783 
human tissue samples (ist.medisapiens.com). The gene tissue index (GTI) outlier statistics (Mpindi 
et al. 2011) was used to measure and rank the outlier genes that are highly expressed in GIST in 
comparison with histologically normal gastrointestinal tract tissue samples. The GTI is a modified 
version of the poverty index formula used in economics. A large positive GTI for a gene indicates an 
outlier in the disease group and a large negative GTI an outlier in the control group. The outlier 
analysis of mRNA expressions in the database was based on 6 GISTs and 34 histologically normal 
gastrointestinal tract tissue samples (study II) or 77 GISTs and 10,654 to 19,986 reference samples 
(study III). The results were filtered using identified drug target genes from https://www.drugbank.ca
(Wishart et al. 2006).
3. High-throughput drug screening (III)
A total of 217 approved or investigational anti-cancer compounds were used in the study. The 
compounds were dissolved in DMSO and plated in 5 different concentrations covering a 10,000-fold 
concentration range into the wells of 384-well plates. GIST882 (1000 cells/well) and GIST48 cells 
(2000 cells/well) were plated on the compounds on the 384-well plates. The plates were incubated in 
a humidified environment at 37°C and 5% CO2. Cell viability was measured after 72 h incubation 
using the CellTiter-Glo Cell Viability Assay (Promega Inc., Madison, WI, USA) and a PHERAstar 
FS plate reader (BMG Labtech, Ortenberg, Germany). The data were normalized to negative (DMSO) 
and positive (100 μmol/L benzethonium chloride) control wells. The Marquardt-Levenberg algorithm 
was used to estimate the 4-parameter logistic dose–response curves using the Breeze analysis 
platform (Yadav et al. 2014). Drug responses to the test compounds were measured using the drug 
sensitivity score (DSS). A high DDS indicates high responsiveness of the cells to a drug.
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4. Immunohistochemistry (I, II, III)
Tissue microarrays were constructed from the representative parts of the formalin-fixed paraffin-
embedded tumor tissues using a 0.6 mm (the mixed tumor series and the Western Sweden series) or 
a 1.0 mm diameter needle (the SSGXVIII/AIO series). Protein expressions were evaluated from 5 
μm tissue microarray sections by immunohistochemistry. The sections were deparaffinised in xylene 
and hydrated in a graded series of alcohol. Prior to staining, hydrogen peroxide was used to block 
endogenous peroxidase activity. Antigen retrieval methods and antibodies used are represented in the 
Table 1. All antibody dilutions were done in a PowerVision preantibody blocking solution and 
incubated either 30 minutes at room temperature or overnight at 4°C (Table 1). Primary antibody 
binding was detected by using a BrightVision+ Histostaining kit (Immunologic BV, Duiven, The 
Netherlands) following the manufacturer’s instructions. The slides were counterstained with Mayer´s 
hematoxylin. Expression of the studied proteins in tumor cells was scored as either negative (less than 
10 % tumor cells stained, study III; less than 20 % tumor cells stained, study I) or positive; or 
categorized as a negative low or high expression based on staining intensity (study II).  The 
immunostainings were analyzed blinded without knowledge of the clinical or histopathological data. 
Table 1. List of antibodies used in immunohistochemistry.
Protein Antibody Dilution Incubation time Pre-treatment buffer Manufacturer
DOG1 NCL-L-DOG-1 1:250 Overnight at +4°C EDTA + water bath Novocastra
ITGA4 A9385 1:100 30 min at RT Sodium citrate + autoclave LifeSpan BioSciences
KIT A4502 1:300 Overnight at +4°C Sodium citrate + water bath DAKO
PDE3A HPA014492 1:100 30 min at RT Sodium citrate + autoclave SIGMA
PDE3B HPA024342 1:20 30 min at RT Sodium citrate + autoclave SIGMA
SLFN12 ab113238 1:50 Overnight at +4°C Sodium citrate + autoclave Abcam
SLUG 9585 1:50 Overnight at +4°C Sodium citrate + autoclave Cell Signaling Techn.
5. Quantitative PCR (II, III)
RNA was extracted from the FFPE tissue sections using a High Pure RNA Paraffin kit (Roche 
Diagnostics GmbH, Mannheim, Germany) and from the cell lines using the NucleoSpin® RNA kit
(Macherey-Nagel, Düren, Germany). The mRNA was reverse transcripted to cDNA with a 
SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. 
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PDE3A and PDE3B mRNA expression levels were quantified in 7 GIST tissue samples and in 30 
leiomyosarcoma samples, two GIST cell lines (GIST882, GIST48) and GIST xenograft tumor 
samples. ITGA4 mRNA expression levels were quantified in 13 GISTs, 29 leiomyosarcomas, 8 
synovial sarcomas and 9 undifferentiated pleomorphic sarcomas. These qPCR samples were selected 
at random from the mixed tumor patient series.
PDE3A, PDE3B and ITGA4 mRNA expressions were quantitated with real-time PCR using 
hydrolysis probes (i.e., hybridization probes labelled with a reporter dye and a quenching dye) and a 
LightCycler 480 instrument (Roche Diagnostics GmbH, Mannheim, Germany). cDNA was amplified 
in a 20 μL PCR mixture using LightCycler 480 Probes Master reagents (Roche Diagnostics GmbH, 
Mannheim, Germany) and fluorescein-labelled locked nucleic acid (LNA) hydrolysis probes (Probe 
79 for PDE3A, Probe 10 for PDE3B and Probe 13 for ITGA4) or the LightCycler® Yellow 555-
labeled LNA hydrolysis probes (Probe TBP for PDE3A and Probe G6PD for PDE3B and ITGA4) 
from a Universal ProbeLibrary Set (Roche Diagnostics GmbH, Mannheim, Germany). The PCR 
mixture contained 1× PCR buffer, 100 nmol/L of probe and 200 nmol/L of each primer. The primers 
(Table 2) and the probes were designed using the ProbeFinder program at Assay Design Center of 
Universal ProbeLibrary (www.universalprobelibrary.com; Roche Diagnostics GmbH).
The cycling parameters for PDE3A, PDE3B and ITGA4 were an initial denaturation step at 95°C for 
10 minutes, followed by 45 cycles (PDE3A, PDE3B) or 60 cycles (ITGA4) with denaturation at 95°C 
for 15 seconds, annealing at 60°C for 45 seconds and elongation at 72°C for 45 seconds. The results 
were analysed using the Basic Relative Quantification method (Roche Diagnostics GmbH).
Table 2. The primers used in the quantitative PCR analyses.
ITGA4: Forward: 5′-AGGAAGTTCCAGGTTACATTGTTT-3′
Reverse: 5′-TTAGAAGAGAAATAGAATCTTGGTGGA-3′
PDE3A: Forward: 5′- AAAGACAAGCTTGCTATTCCAAA -3′ 
              Reverse: 5′- GTGGAAGAAACTCGTCTCAACA -3′
PDE3B: Forward: 5′- AACAATGGTATAAGCCTCATTATCAA -3′
              Reverse: 5′- CGAGCCTCATTTAGCACTGA -3′
TBP:      Forward: 5′ - TGAATCTTGGTTGTAAACTTGACC -3′
              Reverse: 5′ - CTCATGATTACCGCAGCAAA -3′
G6PD:   Forward: 5′- GAGCCAGATGCACTTCGTG -3′
              Reverse: 5′- GGGCTTCTCCAGCTCAATC -3′
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6. Cell lines (I, II, III)
GIST882 and GIST48 cell lines were a kind gift from Doctor Jonathan A. Fletcher (Harvard Medical 
School, Boston, Massachusetts, USA). GIST-T1 cell line was purchased from Cosmo Bio (Tokyo, 
Japan). GIST882 (a primary human GIST cell line) harbours a homozygous missense mutation in 
KIT exon 13 encoding a p.K642E mutant oncoprotein. GIST48 (a GIST cell line that progressed after 
an initial response to imatinib) harbors a KIT exon 11 p.V560D missense mutation leading to 
p.V560D and a secondary exon 17 (kinase activation loop) missense mutation leading to p.D820A.  
GIST-T1 (established from a metastatic plural tumor from a GIST of the stomach) is a KIT exon 11 
mutant cell line that has a heterozygous in-frame deletion of 57 bases. All cell lines were 
mycoplasma-tested and the authenticity of the cell lines was confirmed with DNA sequencing. The 
cells were cultured in a humidified 5% CO2 atmosphere at 37°C. GIST882 and GIST48 cells were 
cultured in the RPMI 1640 medium (GIBCO, CA, USA), supplemented with 20% fetal bovine serum 
with 2% penicillin/streptomycin (GIBCO), and GIST-T1 cells were cultured in a DMEM medium 
(Lonza, Walkersville, MD, USA) supplemented with 10% fetal bovine serum with 2% 
penicillin/streptomycin (GIBCO). 
7. siRNAs (I, II, III)
GIST cell lines were transfected using the Lipofectamine 2000 Transfection Reagent (Invitrogen, 
Carlsbad, CA, USA). The cells were serum starved for six hours before transfection in an Opti-MEM 
Reduced Serum Medium (GIBCO). Transfections were done according to the manufacturer's 
instructions adding 5 pmol/L of siRNA onto the GIST882 and GIST48 cells, and 10 pmol/L of siRNA 
onto the GIST-T1 cells. Transfections were done with an ON-TARGET plus Human KIT siRNA, an 
ON-TARGET plus Human PDE3A siRNA, an ON-TARGET plus Human PDE3B siRNA, an ON-
TARGET plus Human ITGA4 siRNA, and an ON-TARGET plus Human SNAI2 (SLUG) siRNA,
which are pools of target-specific siRNAs (Thermo Scientific Dharmacon, Rockford, IL, USA).  The 
ON-Target plus Non-Targeting Pool (Thermo Scientific Dharmacon) was used as a negative control
8. Inhibitors (II, III)
PDE3 inhibitors cilostazol, milrinone and amrinone were purchased from Sigma (St. Louis, MO, 
USA) and anagrelide hydrochloride was purchased from Lancrix (Shanghai, China). BIO1211 and 
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BIO5192, both integrin α4β1 (VLA-4)-specific inhibitors, were purchased from Tocris Bioscience 
(Bristol, UK). Imatinib was purchased from Cayman Chemical Company (Ann Arbor, MI, USA).
Imatinib was reconstituted in water and BIO1211 in PBS.  All other inhibitors were reconstituted in 
DMSO. Cell lines were cultured for 1 day, and then incubated with inhibitors for 1 to 144 hours. Final 
inhibitor concentration of the drugs varied from 0.001 μM to 100 μM. 
9. cAMP and cGMP assays (III)
PDE3 activity changes in the GIST882 and GIST48 cell lines were analyzed indirectly by measuring 
the amount of cAMP and cGMP. GIST cells were treated with cilostazol, milrinone, amrinone, and 
anagrelide hydrochloride for 6 hours, lysed in 0.1 M HCl and the concentration of cAMP and cGMP 
was determined using a cAMP Enzyme Immunoassay kit or a cGMP Enzyme Immunoassay kit 
(SIGMA, St. Louis, MO, USA). 
10. TUNEL assay (I, III)
GIST cell apoptosis was analyzed with a Click-iT TUNEL Alexa Fluor 488 Imaging Assay
(Invitrogen, Carlsbad, CA, USA) after exposure to KIT siRNA, PDE3A siRNA, PDE3B siRNA, and 
SLUG siRNA and anagrelide hydrochloride, imatinib or anagrelide + imatinib combination. GIST882 
and GIST48 cells were plated at a density of 10,000 cells/well or 15,000 cells/well, respectively, in 
96-well plates. After 24 hours of culture the cells were treated with siRNAs or inhibitors. The TUNEL 
assay was performed 72 hours after siRNA transfections, or 24 hours after adding the drugs. Cells 
were photographed (magnification ×200) using an immunofluorescence microscope (Leica 
CTR6000, Leica microsystems, Bannockburn, IL, USA). The frequency of apoptotic cells was 
expressed as the average number of apoptotic cells per one microscope field. 
11. Proliferation assay (I, II, III)
Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay (Roche Diagnostics, Indianapolis, IN, USA). For the assay, 20,000 GIST48 
cells, 15,000 GIST882 cells, and 5,000 GIST-T1 cells were plated in 96-well plates. Cell proliferation 
was analyzed after adding 10 μL of the MTT reagent into each well and incubation for 4 hours at 
37°C, after which 100 μL of the solubilization solution was added, and the cells were incubated at 
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37°C overnight. The plates were read with a Multiscan EX Microplate photometer (Thermo 
Scientific, Rockford, IL, USA) at the wavelength of 540 nm.
12. Invasion assay (II)
The upper chamber of a 24-well transwell (Corning™ Falcon™ Cell Culture Inserts, 8.0 μm pore 
size, Fisher Scientific) was covered with 50 μL of 2.5 mg/mL matrigel containing 5 μg/mL 
fibronectin. 600 μL of the RPMI 1640 medium (GIST882 and GIST48) supplemented with 20% fetal 
bovine serum or 600 μL of the DMEM medium (GIST-T1) supplemented with 10% fetal bovine 
serum and 2% penicillin/streptomycin were added to the lower chamber of the transwell. For the 
assay, 30,000 GIST48 cells, 20,000 GIST882 cells, and 10,000 GIST-T1 cells were plated in a
medium without serum to the upper chamber of the transwell. GIST48 and GIST882 cells were 
incubated for 24 hours and GIST-T1 cells for 96 hours. Cell invasion was measured in 3 separate 
experiments by counting the cells within 10 photographed fields of the microscope (Leica CTR6000, 
Leica microsystems, Bannockburn, IL, USA; magnification ×200). The number of invaded cells was 
expressed as the average number of invaded cells per one microscope field. 
13. Western blotting (I, II, III)
Cultured GIST cell lines were rinsed in PBS (Lonza, Walkersville, MD, USA) and scraped on ice 
into a RIPA lysis buffer (Pierce Biotechnology, Rockford, IL, USA) containing a Pierce Protease and 
Phosphatase Inhibitor Tablet (Thermo Fisher Scientific Inc., Rockford, IL, USA), followed by 
sonication. The protein concentrations were measured using a Pierce BCA Protein Assay Kit (Thermo 
Fisher Scientific Inc.). Ten μg of protein was separated using gel electrophoresis and blotted onto an 
Immobilon-P Transfer Membrane (Millipore, Billerica, MA, USA). The primary antibodies and 
dilutions used are represented in the Table 3. The peroxidase-conjugated AffiniPure Goat Anti-Rabbit
antibody was used as the secondary antibody (dilution 1:10,000; Jackson Immuno Research, West 
Grove, PA, USA). Blot immunostains were treated with a SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Fisher Scientific Inc., Rockford, IL, USA), exposed to an X-ray film, and the films 
were developed with a Kodak Medical X-ray Processor 102 (Eastman Kodak, Rochester, NY, USA). 
48
Table 3. List of antibodies used in Western blotting
Protein Antibody Origin and class Dilution Manufacturer
β-Actin A300-491A Rabbit, polyclonal 1:10000 Bethyl Laboratories
ITGA4 8440 Rabbit, monoclonal 1:1000 Cell signaling technologies
KIT A4502 Rabbit, polyclonal 1:10000 DAKO
p-KIT (Y703) 3391 Rabbit, polyclonal 1:10000 Cell signaling technologies
PDE3A HPA014492 Rabbit, polyclonal 1:1000 SIGMA
PDE3B HPA024342 Rabbit, polyclonal 1:1000 SIGMA
SLFN12 ab113238 Rabbit, polyclonal 1:1000 Abcam
SLUG 9585 Rabbit, monoclonal 1:1000 Cell signaling technologies
14. mRNA and miRNA sequencing (III)
GIST882 and GIST48 cells were plated at a density of 900,000 cells/ on 6-well plates. After 24 hours, 
GIST cells were treated with 10 μM anagrelide. The cells were scraped into a lysis buffer at time 
points 0 h, 8 h, 24 h and 48 h and for miRNA sequencing at time points 0 h, 1 h, 8 h and 48 h.  RNA 
extractions were done by NucleoSpin® RNA kit (Macherey-Nagel) and DNA extractions were done 
by QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA). Sequencing was performed at BGI 
(Shenzhen, China) using an Illumina HiSeq 2000 sequencer (Illumina, San Diego, CA, USA). 
15. Mass spectrometry (III)
GIST882 and GIST48 cells were plated in the T-75 bottles, grown until 80 % confluence, and then 
treated with 10 μM of anagrelide hydrochloride for 24 h or 48 h, after which, cells from three replicate 
samples were scraped into an 8 M UREA. Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) was performed with an Orbitrap Elite hybrid mass spectrometer coupled to an EASY-nLC 
II system (Thermo Fisher Scientific). LC-MS/MS analysis, MS1 quantification and subsequent 
protein identification were performed as described in elsewhere (Loukovaara et al. 2015). For protein 
identification, the scan data acquired from LC-MS/MS were searched against the human component 
of the UniProtKB- database (release 2014_01) using SEQUEST search engine in Proteome 
Discoverer software (Thermo Fisher Scientific). Maximum one missed cleavage was allowed.   
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16. mRNA and miRNA sequencing data analysis (III)
SePIA (Sequence Processing, Integration, and Analysis) comprehensive transcriptomics workflow 
was used to quality control, pre-process and analyse the miRNA and mRNA data (Icay et al. 2016).
Standard adapter and quality trimming (Bolger et al. 2014), read alignment (Dobin et al. 2013, 
Langmead et al. 2009) and quantification (Anders et al. 2015, Trapnell et al. 2012) were performed 
using SePIa. Normalization and differential analysis of miRNA expression between GIST882 and 
GIST48 at four times points was performed with the R package DESeq (Anders and Huber. 2010), a 
nominal P value of 0.01 was used. Normalized expression was used to identify significant, inversely 
correlated miRNA and mRNA expression (P ≤ 0.05 and Pearson correlation coefficient ≤ -0.7). These 
miRNA-mRNA pairs were then cross-filtered with target prediction databases (Griffiths-Jones et al. 
2008, Grimson et al. 2007, Kertesz et al. 2007, Maragkakis et al. 2009) so that a pair was supported 
by at least one database. Fold-change values were calculated for each of these miRNAs and target 
genes using average expression values in each cell line. Gene fold-change values were used as input 
for signal pathway impact analysis (SPIA (Tarca et al. 2009)). Genes and their predicted targeting 
miRNAs were then identified for each significant pathway (SPIA pGFDR ≤ 0.1).
17. GIST xenografts (III)
The GIST xenograft mouse models were generated in prof. Patrick Schöffski’s laboratory (KU 
Leuven, Belgium). One model was based on the GIST882 cell line and three models were patient-
derived. The GIST882 model (with KIT exon 13 mutation leading to p.K642E) and the UZLX-GIST3 
model (with KIT exon 11 mutation leading to p.W557_V559delinsF) were considered imatinib-
sensitive. The UZLX-GIST2B model was considered dose dependently imatinib-sensitive (with KIT
exon 9 mutation leading to p.A502_Y503dup) and UZLX-GIST9 imatinib-resistant (with KIT exon 
11 mutations leading to p.P577del and W557LfsX5, and a secondary KIT exon 17 mutation leading 
to p.D820G).
 
Adult female athymic Naval Medical Research Institute mice (NMRI nu/nu, Janvier Laboratories, Le 
Genest-Saint-Isle, France) were transplanted by subcutaneous inoculations of GIST882 cells or 
subcutaneous transplantation of biopsies on both sides bilaterally as described previously (Floris et 
al. 2009). Mice were 10-12 weeks old at the time of the transplantation and randomly assigned to 
different treatment groups. Two control mice cohorts were used, one treated with 10% ethanol 
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(vehicle for anagrelide, bid), and one with imatinib (100 mg/kg/qd). The test mice were treated with 
anagrelide (5 mg/kg/bid) or with the combination of anagrelide and imatinib. Effectiveness of the 
treatment in the anagrelide group was compared to the control groups. Each group consisted of 4 to 
6 mice. The tumor volumes (measured 3 times per week) and the mice body weight (measured daily) 
was assessed for 10 to 29 days until the mice were sacrificed (or when the tumor diameter exceeded 
2 cm, the loss of the bodyweight was >20 %, or for another ethical reason).
Both frozen tissue samples and FFPE tissue samples were collected from the sacrificed mice for 
molecular analyses (Table 4 and 5). The FFPE tumor specimens were cut to 4-μm sections for staining 
with haematoxylin and eosin (H&E) and for immunohistochemistry. The quantity of tumor necrosis, 
myxoid degeneration and/or fibrosis was evaluated on the H&E stained slides, and graded as either 
grade 1 (0 %–10 %), grade 2 (>10 % and ≤50 %), grade 3 (>50 % and ≤ 90%) or grade 4 (>90 %) as 
described elsewhere (Antonescu et al. 2005).
The patient-derived GIST model xenografting was approved by the Medical Ethics Committee, 
University Hospitals Leuven (Leuven, Belgium). The in vivo experiments were approved by the 
Ethics Committee for Animal Research, KU Leuven (Leuven, Belgium) and were conducted 
according to their guidelines and Belgian regulations.
Table 4. List of antibodies used in xenograft immunohistochemistry.
Protein Antibody Dilution Incubation time Pre-treatment buffer Manufacturer
Cleaved PARP Ab32064 Ready to use 1 h at RT Reveal decloaker Abcam
+ water bath
DOG1 NCL-L-DOG-1 1:250 30 min at RT EDTA Novocastra
+ water bath
Ki-67 RM9106 Ready to use 30 min at RT Sodium citrate Thermo 
+ water bath scientific
p-AKT 4060 1:25 Overnight at +4°C Sodium citrate Cell signaling
+ water bath technologies
p-Histone H3 9701 1:100 Overnight at +4°C Sodium citrate Cell signaling
+ water bath technologies
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Table 5. List of antibodies used in xenograft Western blotting.
Protein Antibody Origin and class Dilution Manufacturer
AKT 9272 Rabbit, polyclonal 1:1000 Cell signaling technologies
pAKT (S473) 9271 Rabbit, polyclonal 1:1000 Cell signaling technologies
Histone H3 4499 Rabbit, monoclonal 1:1000 Cell signaling technologies
pHistone H3 9701 Rabbit, polyclonal 1:1000 Cell signaling technologies
KIT A4502 Rabbit, polyclonal 1:5000 DAKO
pKIT (Y719) 3391 Rabbit, polyclonal 1:1000 Cell signaling technologies
pKIT (Y703) 3073 Rabbit, polyclonal 1:1000 Cell signaling technologies
MAPK 9102 Rabbit, polyclonal 1:1000 Cell signaling technologies
pMAPK 4370 Rabbit, monoclonal 1:1000 Cell signaling technologies
Tubulin 2128 Rabbit, monoclonal 1:1000 Cell signaling technologies
18. Statistical analysis (I, II, III)
The frequency tables were analysed with the chi2 test or Fisher’s exact test. The Kaplan-Meier 
method, the univariable Cox proportional hazards model, and the log rank test were used to estimate 
the cumulative survival. Overall survival was calculated from the date of the GIST diagnosis to the 
date of death, censoring patients who were alive on the last date of follow-up. GIST-specific survival 
was computed from the date of the diagnosis to death deemed to result from GIST, censoring patients 
who died from another cause on the date of death and patients who were alive on the last date of 
follow-up. Recurrence-free survival (RFS) was calculated from the date of randomization to the date 
of GIST recurrence or to death, whenever death preceded recurrence, censoring the patients alive on 
the date of last follow-up. The interaction between tumor SLUG expression and imatinib treatment 
in the SSGXVIII/AIO series (study I) was calculated using a Gaussian process model for conditional 
event probabilities (Joensuu et al. 2012). The Mann-Whitney test or the Kruskal-Wallis test was used
to compare the continuous parameters. Comparisons between the groups in the TUNEL analysis, 
proliferation analysis, invasion analysis, cAMP and cGMP analyses, histopathologic results and 
tumor volume between different mice treatment groups were done using the Mann–Whitney U-test. 
The Wilcoxon matched paired test was used for tumor volume comparisons between day 1 and at the 
end of every in vivo experiment. All P values are 2-sided. The statistical calculations were done using 
the IBM SPSS Statistics package v. 22.0 (IBM, Armonk, NY, USA), STATISTICA 13.0 (Dell 
Statistica, Tulsa, OK, USA) or GPstuff 4.6 (Vanhatalo et al. 2013).
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RESULTS
1. SLUG, ITGA4, PDE3 expression, clinical factors and disease outcome (I, II, III)
We investigated the MediSapiens in silico database of human transcriptomes for genes that are highly 
expressed in GISTs, and those with protein products known as drug targets, to identify potential driver 
oncogenes in GIST. The outlier statistics was performed with the gene-tissue index (GTI) analysis. 
ITGA4, PDE3A and PDE3B mRNA expressions were high in GISTs as compared with other types of 
cancer and healthy gastrointestinal tract tissues. Similarly, the analysis identified genes that are well 
known to be overexpressed in GIST such as KIT, anoctamin 1 (ANO1) and protein kinase C theta
(PRKCQ). PDE3A and PDE3B mRNAs were expressed particularly in GIST.
The expression of SLUG, ITGA4, PDE3A and PDE3B were studied in three different clinical cancer 
patient series and analyzed by immunohistochemistry. SLUG expression was present 125 (25.0 %) 
out of 500 GISTs, ITGA4 expression 106 (52.2 %) out of 203 GISTs, PDE3A was expressed in 50 
(90.9 %) of the 55 GISTs investigated, and PDE3B in 33 (60.0 %). ITGA4, PDE3A and PDE3B 
expression was also detected in other cancer types like leiomyosarcoma, another common type of 
abdominal sarcoma, but much less frequently than in GIST. SLUG expression was studied only in 
GIST sample series but SLUG expression has been described in a wide spectrum of human cancers 
(Cobaleda et al. 2007). In Studies II and III the the specificity of immunostaining was examined by 
comparing the protein expression at immunohistochemistry with mRNA expression measured with
qPCR (P ≤ 0.001 in both studies). 
The clinical significance of protein expressions was investigated in two series of GIST patients (the 
Western Sweden study and the SSGXVIII/AIO trial for high risk patients). In the Western Sweden 
series SLUG and ITGA4 were associated with presence of tumor necrosis, a high tumor mitotic count 
and presence of metastases at the time of GIST detection. In addition, SLUG was associated with a 
large tumor size at the time of the diagnosis, epithelioid type of tumor histology and nuclear 
pleomorphism; and ITGA4 with a tumor location in the stomach, a high NIH risk stratification group 
for recurrence (all P values < 0.05). In the SSGXVIII/AIO study tumor SLUG expression was 
significantly associated only with the presence of tumor rupture in high risk patients.
53
Patients whose GIST expressed SLUG had less favorable overall and recurrence free survival (RFS) 
than patients whose GIST did not express SLUG (P = 0.006 and P = 0.001, respectively). Whereas 
ITGA4 expression was associated with poor overall survival and GIST-specific survival (P = 0.044 
and P = 0.008, respectively). The associations of clinical factors with PDE3A and PDE3B protein 
expression was also studied in the population-based Western Sweden series, but no significant 
correlations for clinicopathological factors and RFS or overall survival were found (P > 0.05, 
unpublished data). In the SSGXVIII/AIO trial, high risk patients with SLUG-positive tumor had 
inferior RFS as compared to patients whose GIST did not express SLUG (P = 0.001). 
2. Effect of SLUG or ITGA4 downregulation on GIST cell lines (I, II)
As SLUG and ITGA4 expressions were associated with various clinical high-risk features and 
unfavorable survival, the function of these proteins was further investigated in the GIST cell lines. 
The function of SLUG was investigated in GIST48 and GIST882 cell lines. Additionally, ITGA4 
expression was studied in GIST-T1 cell line. Both SLUG and ITGA4 were present in the GIST cell 
lines. SLUG was, however, expressed substantially more weakly in GIST882 as compared with 
GIST48.
Both tumor SLUG and ITGA4 expressions were associated with a high GIST cell proliferation rate 
in the Western Sweden series, and we investigated whether SLUG or ITGA4 expression promote 
GIST cell viability using the MTT assay. SLUG RNA knockdown reduced cell proliferation in 
GIST48 and GIST882 cell lines (P < 0.001 for each cell line). In addition, downregulation of SLUG 
increased cell death in these cell lines when the numbers of dying cells were measured using the 
TUNEL assay. In the GIST48 cell line, the mean proportion of dying cells increased from 10.7% (SE 
= 1.8%) in the control to 28.4% (SE = ±4.2%, P = 0.008) after treating the cells with SLUG siRNA. 
Similarly, in the GIST882 cell line SLUG siRNA transfection increased the mean proportion of DNA 
fragmentation in nuclei from 18.3% (SE = ±2.6%) in the control siRNA to 33.2% (SE = ±5.1%, P =
0.029). In GIST882 cell line, downregulation of SLUG showed synergy with imatinib and sensitized 
cells to imatinib-induced apoptosis. 
Blocking of ITGA4 by RNA interference had no effect on the proliferation of the 3 GIST cell lines 
(all P-values > 0.05). VLA-4 (α4β1) inhibition by BIO1211 and BIO5192 had only little effect on 
proliferation. The effect of ITGA4 downregulation and VLA-4 inhibition for GIST cell invasion was 
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further evaluated in a matrigel-coated transwell system. The number of invaded cells decreased in all 
GIST cell lines after ITGA4 siRNA transfection as compared with the control siRNAs (GIST48, 
mean = 8.3 vs. control mean = 23.2, P = 0.016; GIST882, mean = 3.4 vs. control mean = 29.7, P =
0.014; and GIST-T1, mean = 1.5 vs. control mean = 17.4, P < 0.001). Similarly, the number of 
invaded cells decreased in each GIST cell line after VLA-4 inhibitor treatments. However, in 
GIST882 and GIST-T1 cell lines, only BIO1211 decreased the numbers of invaded cells significantly. 
3. Effect of PDE3 inhibition on GIST cell proliferation and signaling (III)
GIST48 and GIST882 cell lines were first tested for sensitivity to 217 drug compounds. The drug 
response profiles were compared with the expression of the top 25 genes that were highly expressed 
on GIST based on the GTI-analysis. Various tyrosine kinase inhibitors including axitinib, dasatinib, 
foretinib, imatinib, nilotinib, ponatinib, sorafenib, sunitinib and tivozanib reduced the viability of 
GIST cells. Unexpectedly, a phosphodiesterase 3 inhibitor, anagrelide, which is marketed for the 
treatment of patients with thrombocytemia, was also effective on the GIST882 cells.
The effect of anagrelide and three other PDE3 inhibitors were next investigated closer in the GIST48 
and GIST882 cell lines. As expected, anagrelide induced a strong cytotoxic effect on GIST882 cell 
line ((IC50=0.016 μM). The efficacy of anagrelide was comparable to the effect of imatinib. 
However, the anagrelide was only weakly active in the GIST48 cell line. The anagrelide plus imatinib 
combination decreased the proliferation of GIST cells substantially compared to single agent 
treatments. Amrinone, cilostazol and milrinone had no effect on GIST48 or GIST882 cell 
proliferation.
We investigated further the effect of anagrelide and the combination of anagrelide and imatinib in 
GIST cells with TUNEL assay that detects the fragmented DNA and the proportion of apoptotic cells. 
21.7 % of the anagrelide-treated GIST882 cells were apoptotic, while only slight DNA fragmentation 
was seen in GIST48 cell line. In GIST882 cells treated with imatinib, the proportion of apoptotic cells 
was comparable to anagrelide-treated cells. In GIST48, cells imatinib increased cell death to 32.1 % 
as compared to control. In addition, a larger proportion of the cells entered apoptosis in both GIST 
cell lines when imatinib and anagrelide were co-administered. 36.8 % of GIST882 cells and 44.1 % 
of GIST48 cells were apoptotic after the combination treatment.
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The effect of four PDE3 inhibitors on the PDE3 activity were analyzed by measuring changes in the 
intracellular cAMP and cGMP levels in the GIST cell lines. An increase in the intracellular cAMP 
and cGMP in response to PDE3 inhibition was observed in both GIST cell lines. Of the compounds 
tested, anagrelide inhibited the PDE3 enzyme activity most effectively.  Increase of cAMP was 
greater in GIST882 cells, where all four PDE3 inhibitors induced a significant increase (P < 0.05), 
while only milrinone and anagrelide induced significant increase in GIST48 cells. Similarly, the 
cGMP level changes were more remarkable in GIST882 cells. In GIST882 cells milrinone and 
anagrelide and in GIST48 cells anagrelide increased the cGMP levels significantly.
The role of PDE3A and PDE3B in GIST cells were investigated by blocking their expression using 
small interfering RNAs. The inhibition of PDE3A did not influence GIST cell proliferation. PDE3B 
downregulation decreased the proliferation of the GIST882 cell line (P < 0.01), whereas only weak 
decrease of proliferation was seen in the GIST48 cell line (P < 0.05).
In addition, we treated GIST882 cells with a combination of PDE3 siRNAs and increasing 
concentrations of anagrelide. PDE3B siRNA and the combination PDE3A siRNA and PDE3B siRNA 
increased the cytotoxic effect of anagrelide, whereas PDE3A siRNA decreased the sensitivity to 
anagrelide. None of the treatments influenced GIST48 viability. GIST cells were treated also with 0.5 
μM anagrelide and rising concentrations (from 0.0001 μM to 30 μM) of PDE inhibitors cilostazol, 
milrinone or amrinone for 72 hours. Cilostazol and milrinone rescued cell death induced by anagrelide 
in GIST882 cells, whereas amrinone had no effect, and none of the treatments had an effect on the 
viability of GIST48 cells.
Downregulation of KIT or PDE3B with siRNAs increased apoptosis in both cell lines. In the GIST48 
cell line, the mean proportion of dying cells increased from 10.7% in the control to 27.4% (P = 0.078) 
after treating the cells with PDE3B siRNA and to 34.7 % (P < 0.001) after treating the cells with KIT 
siRNA. In the GIST882 cell line PDE3B and KIT siRNA transfections increased the mean proportion 
of DNA fragmentation from 18.3% in the control siRNA to 57.3 % (P < 0.001) and to 35.4 % (P =
0.045), respectively. PDE3A or PDE3B knockdown had no effect on KIT or phospho-KIT expression 
on GIST cell lines. Indicating that PDE3 signaling is may not be directly linked to KIT signaling. In 
previous a study of de Waal et al. speculated that anagrelide might promote the interaction between 
PDE3A and SLFN12 (de Waal et al. 2016). We studied if SFLN12 is expressed in GIST cells, but 
found no SLFN12 expression.
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GIST cell line mRNA and miRNA expressions were studied using RNA-sequencing to identify the 
essential signaling pathways that were affected by anagrelide treatment, and the protein expression 
was investigated using label-free liquid chromatography-mass spectrometry. Comprehensive 
transcriptomic data analysis and integration workflow, SePIA, was used to identify genes whose 
expression patterns were inversely correlated with miRNA expression patterns and accumulated 
perturbations in the corresponding signaling pathways. The pathway perturbations were compared 
between the GIST882 cell line (anagrelide sensitive) and in GIST48 cell line (anagrelide insensitive), 
and the most remarkable changes were found within the pathways such as cell cycle, focal adhesion, 
oocyte meiosis, protein processing in the endoplasmic reticulum, insulin signaling, p53 signaling, 
TGF-beta signaling, Wnt signaling and neurotrophin signaling. The protein expression of the cell 
lines was next correlated with the significantly regulated and enriched genes in the perturbation 
pathways. Fifteen proteins including YWHAQ, PPP1CB, EIF4E, CALM2 and RAD23B showed 
complete overlap with mRNA expression and an inverse correlation with miRNA expression.
4. PDE3 inhibition in GIST xenograft mouse models (III)
We studied the in vivo efficacy of anagrelide in a GIST822 cell line xenograft model and in three 
patient-derived GIST xenograft mouse models. The tumor growth inhibition or size reduction was 
found in three out of the four models. The most potent response was seen in GIST2B that harbors the 
KIT exon 9 p.A502_Y503dup duplication mutation, where anagrelide caused a marked tumor volume 
regression (68%) after 10 days of treatment and was substantially more effective than imatinib. 
Evaluation of the histologic response (HR) showed that anagrelide led to the induction of grade 2 or 
higher HR in 50 % of the GIST2B tumors. The imatinib plus anagrelide combination treatment led 
to a superior HR compared to single agent treatments. 
In the GIST882 xenograft model, imatinib or anagrelide single agent treatments stabilized the tumor 
volume, while their combination treatment resulted in a substantial reduction in the tumor volume. 
Single-agent anagrelide caused a minimal HR (majority grade 1), but a superior HR was observed 
(grade 2/3 in most of the tumors) in the combination treatment group. 
Single-agent anagrelide stabilized the tumor volume (P = 0.09) and led to a grade 2 HR (in 50 % of 
the tumors) in the GIST3 model with KIT exon 11 indel mutation (p.W557_V559delinsF). In this 
model imatinib was, however, more effective than anagrelide leading to significant tumor regression. 
57
In addition, the effect of the combination of anagrelide plus imatinib on the tumor growth was similar
to single agent imatinib treatment. However, a more marked HR was achieved with the anagrelide 
plus imatinib combination as compared the single agent treatments. None of the treatments tested was 
effective in the GIST9 model with KIT primary exon 11 mutation and a secondary KIT exon 17 
mutation, although the tumors grew slightly slower in all treatment groups as compared to the control 
group. 
The anti-proliferative and apoptotic activities of the different drug treatments was evaluated with the 
H&E staining and with immunohistochemistry for phospho-histone H3, Ki67 and cleaved PARP
expression. The control tumors showed a high proliferative activity in all tumor models (an average 
of 40 mitotic cells per 10 high power fields). Anagrelide treatment reduced significantly the cell 
proliferation rate in the GIST2B and GIST3 models compared to the control groups (P ≤ 0.005). A
combination treatment with anagrelide and imatinib reduced significantly the mitotic activity 
compared to single-agent treatments in the GIST882 and GIST2B models. Anagrelide increased 
apoptosis in the GIST3 and GIST882 models compared to the control groups. In addition, the 
combination treatment induced a more potent apoptotic activity compared to imatinib or anagrelide 
alone in these two models (the mouse xenograft cell proliferation and apoptotic rate results are 
unpublished data). 
The effect of anagrelide on KIT signaling and the effect of imatinib on PDE3 levels was evaluated 
by Western blotting. Anagrelide had no effect on KIT signaling in any of the GIST models. However, 
in GIST3, GIST2 and GIST882 models the combination treatment reduced tumor KIT and AKT 
levels, which may be caused by a higher HR (greater tumor necrosis and small cell viability) than the 
actual downregulation of these proteins. None of the treatments influenced markedly GIST PDE3A 
or PDE3B expression levels. GIST PDE3 expression levels showed no obvious association with 
response to anagrelide, but, interestingly, in the treatment-resistant GIST9 model the PDE3A to 
PDE3B ratio was the highest. We investigated also whether SLFN12 is expressed in the GIST 
xenograft mouse models. Interestingly, the SLFN12 expression increased in anagrelide treated tumor 
tissues compared to the control group.
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DISCUSSION
Several multikinase inhibitors are highly effective in the treatment of the most patients with advanced 
GIST (Bauer and Joensuu. 2015), but secondary drug resistance to imatinib and other tyrosine kinase 
inhibitors usually eventually develops leading to GIST progression (Heinrich et al. 2006). The second
and the third line treatments with the approved multikinase inhibitors sunitinib (Demetri et al. 2006)
and regorafenib (Demetri et al. 2013) are effective, but the responses are often of short duration, and 
neither commercially available treatment is curative, causing an unmet clinical need in GIST therapy. 
Clinical studies and new therapy options are heavily focused on the receptor tyrosine kinase 
inhibitors. In the present thesis, we investigated the role of SLUG, ITGA4 and PDE3s as novel 
therapeutic targets for the treatment of GIST patients.
1. SLUG is a pro-survival and prognostic factor in GIST
The role of KIT receptor tyrosine kinase in GIST formation is well established, but the molecular 
mechanism beyond KIT signaling are still incompletely understood. The E-twenty-six (ETS) family 
transcription factor ETV1 is a regulator of the interstitial cells of Cajal (ICC) lineage and has a key 
role in the development of GIST (Chi et al. 2010). Further, it was found that the forkhead family 
member FOXF1 controls the transcription of two GIST master regulators, KIT and ETV1 (Ran et al. 
2017). We investigated whether the transcription factor SLUG, which has been linked with the KIT 
signaling pathway (Motro et al. 1991, Perez-Losada et al. 2002, Sanchez-Martin et al. 2003), also has 
a function in GIST tumorigenesis. The clinical significance of SLUG in GIST has not been reported 
previously. We found that SLUG is expressed in 25 % of GISTs and that the SLUG expression was 
associated with unfavorable RFS in two separate clinical series. In addition, SLUG was associated 
with several known risk factors for GIST recurrence and metastases such as presence of tumor 
rupture, a high tumor mitotic count and presence of metastases at the time of GIST detection. 
However, in the present study SLUG expression was not associated with non-gastric tumor location, 
which is considered an established adverse prognostic factor in GIST (Joensuu et al. 2016).
In line with our findings, patients with SLUG-positive cancers have poor clinical outcomes in several 
human cancer types such as breast cancer, colorectal cancer, lung cancer and esophageal cancer (Liu 
et al. 2013, Shioiri et al. 2006, Uchikado et al. 2005, Wu et al. 2015). Consequently, tumor SLUG 
expression is likely an adverse prognostic feature in various human cancers. We found that SLUG 
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expression in GIST is a relatively strong adverse factor in univariable survival analyses of two GIST 
patient series, and it had independent prognostic value in a trial including high risk patients treated 
with surgery and adjuvant imatinib. However, in our series most of even high-risk GISTs did not 
express SLUG proposing that elevated SLUG expression may not invariably be related to tumor 
progression in GIST.
SLUG downregulation decreased cell viability and increased cell death in prostate cancer and 
neuroblastoma (Emadi Baygi et al. 2010, Vitali et al. 2008). In leiomyosarcomas the knockdown of 
SLUG was associated with decreased cell proliferation and invasion (Yang et al. 2010). Interestingly, 
the combination of SLUG knockdown plus imatinib inhibited also the metastatic growth of 
neuroblastoma in an in vivo model, while imatinib as a single agent was unable to reduce the 
metastatic burden (Vitali et al. 2008). Similarly, we found that blocking of SLUG expression reduced 
GIST cell proliferation and increased apoptosis. Downregulation of SLUG showed synergy also with 
imatinib on GIST882 cell line proliferation and sensitized cells to imatinib-induced apoptosis. In 
ovarian cancer cells SLUG contributes to cisplatin resistance, and SLUG silencing increases the 
sensitivity of ovarian cancer to drug treatment (Haslehurst et al. 2012). It has been suggested that 
SLUG may prevent apoptosis either by regulation of caspases or repressing expression of the pro-
apoptotic PUMA protein (Tribulo et al. 2004, Wu et al. 2005). SLUG has a central role in a signaling 
involved in survival and imatinib resistance in chronic myeloid leukemia progenitor cells (Mancini 
et al. 2010). Similar mechanisms may also contribute drug resistance in GIST, and SLUG might 
contribute to imatinib resistance in GIST. SLUG may mediate cell survival and drug resistance in 
cancer cells by regulation set of genes functioning in various signaling pathways. Transcription 
factors ETV1 and FOXF1 have been described as a potential new therapy targets in GIST (Chi et al. 
2010, Ran et al. 2015, Ran et al. 2017). Theoretically, imatinib and SLUG down-regulation could be 
combined for the treatment of some malignancies including GIST, but the means to deliver effective 
anti-SLUG therapy efficiently and safely are currently lacking. However, novel technologies such as 
proteolysis targeting chimeras (PROTACs) that use bifunctional small molecules to link the target 
proteins to the E3 ubiquitin ligase system for protein degradation may provide a new option for the 
therapeutic targeting of transcription factors (Deshaies. 2015).
The molecular mechanisms how KIT signaling may regulate SLUG are controversial. In colorectal 
cancer cell lines KIT expression suppressed SLUG (Gavert et al. 2013), but KIT increased SLUG 
expression and KIT downregulation decreased SLUG expression in malignant mesothelioma and 
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neuroblastoma cells, whereas upregulation of KIT increased SLUG expression in leukemia cells
(Catalano et al. 2004, Lau et al. 2015, Perez-Losada et al. 2002). Taken together, SLUG signaling is 
likely influenced also by other factors than KIT, and this may occur in a tumor phenotype-dependent 
manner. A recent study shows that the forkhead box (FOX) family transcription factor FOXF1
controls the transcription of two key regulators, KIT and ETV1, both likely frequently required for 
GIST tumorigenesis (Ran et al. 2017). As a potential core-controller of the GIST pathogenesis, 
FOXF1 may influence also on SLUG signaling.
2. Integrin alpha 4 (ITGA4) contributes to GIST invasion
Relatively little is known about the molecular factors that influence the invasive and metastatic 
properties of GIST. Integrins mediate a wide variety of cellular effects and signalling that can result 
in tumor progression and metastasis in various types of human cancer (Desgrosellier and Cheresh. 
2010) but their significance in GIST is poorly understood. It is not unexpected that integrins may be 
important also in the molecular pathogenesis of GIST. At present, the role of ITGA4 is unknown in 
GIST. 
ITGA4 was expressed in over 50 % of GISTs, and the expression was associated with high mitotic 
counts, tumor necrosis, poor survival and a presence of distant metastases during the course of 
disease. These observations are in line with the earlier reported role of α4 integrins in the embryonal 
development, normal tissues, and in cancer. The alpha 4 integrins are expressed especially during 
hematopoiesis on early pluripotent progenitor cells, eosinophils, and mononuclear leukocytes
(Arroyo et al. 1999). The alpha 4 integrins mediate cell-cell adhesions that may be important also for
the immune functions (Kinashi. 2012). They have an important role in leukocyte trafficking, and they 
may be involved in the pathogenesis of several chronic diseases including multiple sclerosis, 
rheumatoid arthritis, contact hypersensitivity, and inflammatory bowel diseases (Abraham et al. 1994, 
Chisholm et al. 1993, Yednock et al. 1992). Natalizumab, a recombinant humanized monoclonal 
ITGA4 antibody, has demonstrated clinical activity in patients with relapsing multiple sclerosis and 
Crohn’s disease (Ransohoff. 2007, Rutgeerts et al. 2009).
Although ITGA4 is known to influence especially cell migration and invasion, it may also have an 
effect on cell proliferation. Activation of ITGA4 leads to tumor inflammation and the growth of
myeloid cells (Schmid et al. 2013), whereas, natalizumab may decrease multiple myeloma
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progression by blocking the interaction between multiple myeloma cells and the bone marrow stromal 
cells (Podar et al. 2011). In our clinical GIST patient series ITGA4 expression was strongly associated 
with a high tumor mitotic count. However, the knockdown of ITGA4 or the inhibition of VLA-4 had 
no effect on the GIST cell proliferation. ITGA4 expression is associated with poor prognosis 
especially in chronic lymphocytic leukemia, but also in neuroblastoma (Buggins et al. 2011, Bulian 
et al. 2014, Young et al. 2015). In agreement with these observations, tumor ITGA4 expression was 
associated with with poor overall and GIST-specific survival in our GIST patient series. ITGA4 and 
VCAM-1 interaction increases the metastatic capacity of beta2/beta3-negative melanoma cells
(Klemke et al. 2007), and downregulation of VLA-4 (α4β1) in a MV3 melanoma in vivo model with 
heparin derivatives reduces melanoma metastatic potential (Schlesinger et al. 2012). We found a 
positive association between GIST ITGA4 expression and metastatic disease in a GIST patient series,
and downregulation of ITGA4 mRNA expression or VLA-4 inhibition in GIST cell lines decreased 
the invasion of GIST cells. The role of ITGA4 in GIST progression relate more likely with the 
contribution of ITGA4 to tumor invasion and dissemination rather than to cell proliferation.
It has been suggested that ITGA4 has a role in cancer drug resistance in leukemia. ITGA4 was 
identified as a central mediator of drug resistance of pre-B-cell acute lymphoblastic leukemia, and 
blocking of ITGA4 sensitized leukemia cells to chemotherapy (Hsieh et al. 2013). ITGA4-fibronectin 
interactions on acute myeloid leukemia cells reduce their chemosensitivity (Matsunaga et al. 2003).
In small cell lung cancer ITGA4 signaling mediates adhesion, survival and chemoresistance 
(Hartmann et al. 2005). Further, the ITGA4 - Abi-1 (Abelson interactor-1) signaling pathway and the 
high expression levels of ITGA4 may mediate the imatinib drug-resistance in Bcr-Abl-positive
leukemia (Chorzalska et al. 2014). Abl has structural similarity with KIT that makes this observation 
especially interesting.
The focal adhesion kinase (FAK), one of the key mediators of integrin signaling and a promoter of 
cell migration, is highly expressed in GISTs (Koon et al. 2004, Mitra and Schlaepfer. 2006).
Somewhat unexpectedly, imatinib was found to stimulate the SRC family kinase (SFK) and FAK 
activation, and thus integrin signaling in a mouse KitV558Δ/+ model of GIST in one study (Rossi et al. 
2010) suggesting that integrin signaling may be important for tumor persistence and emergence of 
imatinib resistance. In addition, integrins αvβ1, αvβ3, αvβ5 and their ligand, the neuronal adhesion 
protein L1CAM, are expressed in GIST (Kaifi et al. 2006, Rossi et al. 2010). In accordance with 
earlier results (Rossi et al. 2010), imatinib treatment induced FAK Y397 phosphorylation in GIST48 
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and GIST-T1 cell lines (unpublished data). Both the basal level and imatinib-induced phosphorylation 
of FAK decreased markedly in GIST cell lines after suppression of ITGA4 mRNA, suggesting that 
ITGA4 has a role in the induction of FAK phosphorylation and migration of GIST cells. 
Regardless of the encouraging preclinical results, clinical trials using integrin inhibitors have been 
mostly disappointing (Desgrosellier and Cheresh. 2010). The complexity of integrin function and 
integrin-GFR interaction makes integrins difficult to target, and signaling molecules downstream of 
integrins might be easier to target therapeutically. Several clinical phase 1-2 trials are currently 
ongoing for example with FAK and Src inhibitors, but the therapeutic potential of these drugs is still 
uncertain. 
3. PDE3 family is a potential therapeutic target in GIST
Phosphodiesterases are a useful drug target in a few diseases, and they might be a therapeutic target
in the treatment of some cancers. In the present thesis study, we found that phosphodiesterases have 
a role also in the pathogenesis of GIST and that a phosphodiesterase 3 inhibitor, anagrelide, marketed 
for the treatment of patients with thrombocytemia, might be an active agent in the treatment of GIST.
We found that PDE3A and PDE3B enzymes are expressed especially highly in GIST as compared 
with other human tumors and histologically normal tissues, and propose that PDE3 activity might be 
important especially for GIST viability. Previously, PDE3A was found to be expressed in the gastric 
antrum and in the interstitial cells of Cajal in a GIST murine model harboring a germline KIT mutation 
(K641E) (Gromova et al. 2009). Overexpression of several other phosphodiesterases and reduced 
cAMP or cGMP expression have been found in colorectal cancer, glioblastomas, lung cancer and 
leukemias (Marko et al. 2000, McEwan et al. 2007, Zhang et al. 2008). Several PDE inhibitors have 
also been reported to induce apoptosis or cell cycle arrest in various cancer cell lines, such as breast 
cancer, melanoma and leukemia lines (Marko et al. 2000, Piazza et al. 2001, Saravani et al. 2012, 
Shimizu et al. 2009, Zhang et al. 2008). Interestingly, PDE3A modulator 6-(4-(diethylamino)-3-
nitrophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one (DNMDP) may decrease the viability of 
GIST cells (Vandenberghe et al. 2017). Vandenberghe et al. proposed also that PDE3 inhibitor, 
cilostazol, might reduce the viability of GIST cells. We were not able to replicate these results in our 
cell lines, and observed no effect on GIST cell proliferation after cilostazol treatment. This is in line
with the observation that cilostazol does not replicate the cytotoxic effect of DNMDP in DNMDP-
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sensitive cell lines (de Waal et al. 2016). Of the 11 different PDE families, the PDE3 and PDE4 
families are the key families in the hydrolysis of the cAMP phosphodiester bonds (Conti and Beavo. 
2007). All the PDE3 inhibitors tested had some effect on the AMP and/or cGMP levels in GIST cell 
lines, but anagrelide inhibited the PDE3 activity most effectively.
The role of PDE3s were investigated further by inhibiting the expression of PDE3A and PDE3B in 
GIST cell lines using RNA interference. PDE3B inhibition decreased the proliferation of GIST cells, 
while PDE3A reduction had no effect. The reduction was, however, weaker compared to KIT 
knockdown. The cytotoxic effect of anagrelide may not be caused only by direct inhibition of PDE3A 
or PDE3B enzyme activity. Interestingly, we observed that PDE3A knockdown decreased sensitivity 
to anagrelide, whereas PDE3B knockdown increased anagrelide-induced cytotoxicity. PDE inhibitors 
cilostazol and milrinone rescued anagrelide cytotoxicity suggesting that some PDE3 inhibitors may 
compete with anagrelide for binding to the same molecular target. Anagrelide cytotoxicity requires
PDE3, and the cytotoxic effect of anagrelide may be mediated through modulation of the PDE3 
signalosome complex that is dependent on both PDE3A and PDE3B.
Cyclic nucleotide signaling is organized via the formation of cyclic nucleotide signalosomes, which 
are localized macromolecular complexes that contain precisely recruited cyclic nucleotide effectors
(Maurice et al. 2014). Disruption and interference of these complexes or displacing individual 
complex partners may lead to disturbed function of the signalosome. Some PDE3 inhibitors function 
as competitive inhibitors and occupy the catalytic cAMP or cGMP binding sites (Card et al. 2004, 
Zhang et al. 2002). The binding of DNMDP, a PDE3 modulator, to PDE3A promotes the interaction 
between PDE3A and Schlafen 12 (SLFN12) that mediates the death of Hela cells, whereas depletion 
of PDE3A rescues the cells from death (de Waal et al. 2016). We found that that anagrelide may 
increase the SLFN12 expression in GIST xenograft mouse tissues, but SLFN12 expression is 
probably not required to induce the cytotoxic effect of anagrelide in GIST cells. We found that a 14-
3-3 family protein YWHAQ and protein phosphatase 1 subunit PPP1CB, known partners of the 
signalosomes of PDE3s (Maurice et al. 2014), were dysregulated at both gene and protein expression 
levels after the PDE3 inhibitor anagrelide treatment in the GIST cell lines. 
Phosphodiesterases have been studied as potential anticancer targets in preclinical models (Savai et 
al. 2010), but so far no PDE inhibitor has been approved for the treatment of cancer. Most of the 
anticancer studies have focused on the PDE4 and PDE5 families. Phosphodiesterase inhibition has
64
shown antitumor efficacy especially in hematological malignancy models, in particular those of 
chronic lymphocytic leukemia and acute lymphoblastic leukemia (Lerner and Epstein. 2006, Ogawa 
et al. 2002). The PDE4 inhibitor rolipram attenuated cell proliferation and angiogenesis in a lung 
cancer xenograft mouse model, and reduced tumor growth and enhanced the effects of radiation 
therapy and chemotherapy in gliomas (Goldhoff et al. 2008, Pullamsetti et al. 2013). PDE4D 
inhibitors NVP-ABE171 and cilomilast decreased the growth of prostate cancer cells in vivo (Powers 
et al. 2015). PDE5 inhibitors in combination with chemotherapeutic agents could prevent progression 
and metastasis (Liu et al. 2016), and the PDE5 inhibitor sildenafil induced cell growth inhibition, cell 
cycle arrest and apoptosis of colorectal cancer xenograft mouse models (Mei et al. 2015).
Finally, we investigated the in vivo efficacy of the PDE3 inhibitor, anagrelide, in four GIST xenograft 
mouse models carrying diverse KIT mutations. The tumor volume reduction was observed in one 
model and tumor growth inhibition in two of the models. The most potent effect was observed in a 
GIST xenograft mouse model with KIT exon 9 mutation, which mutations occur in about 10% of all 
GISTs. Patients with KIT exon 9 mutations are also associated with inferior recurrence-free survival 
outcomes as compared with other KIT mutation types (Joensuu et al. 2015). GISTs carrying exon 9 
mutation usually pose a therapeutic challenge, as these GISTs require a high daily dose of imatinib 
(800 mg/day), which often causes considerable adverse effects (Gastrointestinal Stromal Tumor 
Meta-Analysis Group (MetaGIST). 2010). In GIST882 and GIST3 models, single-agent anagrelide 
treatment stabilized the tumor volume, and the combination of anagrelide and imatinib showed a 
synergistic effect on tumor viability. 
Several PDE inhibitors have shown promising preclinical results especially when combined to some 
of the current treatment options. This could be the best approach also in the treatment of GIST. Results 
from a series of patient with chronic myeloproliferative disorders treated with the combination of 
imatinib and anagrelide suggest that their co-administration is feasible in the clinic (Tsimberidou et 
al. 2003). Based on our results, a clinical trial evaluating the effect of anagrelide in the treatment of 
advanced imatinib-resistant GIST seems highly warranted. 
4. Study limitations
The quantitation of protein expression based on immunohistochemistry is subjective and many of the 
antibodies used were polyclonal, increasing the possibility of unspecific antibody binding. The type 
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and quality of tumor tissue used in the study may also have influenced the results, and we cannot 
exclude the effect of factors such as differences in tissue sample fixation. However, the 
immunohistochemistry scoring correlated with tumor mRNA qPCR measurements in a subset of 
cases (P < 0.05, II, III). In addition, the immunohistochemical scorings were compared between two 
independent observers and the agreement turned out to be good. In part, the studies were based on a 
subset of the patients. Therefore, we compared age at the time of the diagnosis, gender, the NIH risk 
classification distribution, and the main GIST prognostic features in the subset available for study
and the entire population-based Western Sweden series. We did not find significant differences 
between the included subset and the entire series in any of these parameters, suggesting that patient 
exclusion caused no major bias. Yet, confirmation of the findings in other GIST series is warranted.
GIST is a relatively rare cancer type, like all sarcomas, and there are only few GIST cell lines 
available, and we had the access only to three of these. The findings from the studied GIST lines 
were, however, generally supportive to the data from the clinical series. The effects of siRNAs are
often of relatively short duration, and the inhibition is rarely perfect. However, the siRNAs used 
turned out to work relatively well, and there was no remarkable variation between repeat experiments. 
Even though we observed that anagrelide is likely to modulate the action of PDE3, we were not able 
to show the exact mechanism of action of anagrelide. 
5. Future studies
Outstanding advances have been achieved in the management of GIST over the last 20 years. Surgery 
remains the standard treatment for localized GIST, and with or without adjuvant imatinib, is 
considered the only curative treatment of GIST. Although imatinib and other tyrosine kinase 
inhibitors have remarkably improved the patient prognoses, drug resistance often eventually 
develops, and, therefore, new drug treatments are needed. In this thesis study, we investigated a few 
proteins that may have potential to function as therapeutic targets in the treatment of GIST.
Further investigation of the studied proteins and especially the effect and possible relationships of 
these proteins, and the ETV1 and FOXF1 transcription factors, might be beneficial. Studies on SLUG 
and ITGA4 in GIST xenograft mouse models might provide further information about the function 
of these proteins. Finding out the exact mode of action of anagrelide would probably be highly 
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valuable. Anagrelide is an old drug, and the co-administration of anagrelide and imatinib is probably 
feasible in the clinic. Therefore, the testing of anagrelide in a clinical trial is highly warranted. 
The gene-tissue index analysis, which ranked the 25 best mRNA expression outlier genes for GIST,
includes a few potential genes such as PLAT, BCHE and NPR3 that could be targeted therapeutically,
and are worth of further studies.
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CONCLUSIONS
The aim of this thesis study was to find novel potential therapeutic drug targets for GIST treatment.
We studied the role of SLUG, ITGA4 and PDE3 in GIST. The frequency of these proteins and their 
association with patient and tumor characteristics and disease outcome was studied with 
immunohistochemistry, and the functional role of the proteins was further investigated in GIST cell 
lines by inhibiting their function with siRNAs or protein specific inhibitors. The role of PDE3 was 
studied in patient-derived xenograft mouse models. 
The main conclusions are the following:
1. SLUG expression was found in about a quarter of GISTs. SLUG expression was associated with 
unfavorable recurrence-free survival of GIST patients. SLUG may function as a pro-survival factor 
in GIST.
2. ITGA4 is highly expressed in GISTs compared to many other human cancers and 
histopathologically normal tissues. The ITGA4 protein expression is associated with several factors 
of unfavorable prognosis and the presence of metastases, and with poor GIST-specific and overall 
survival of the patients. ITGA4 may promote invasiveness and influence the clinical behavior of 
GIST.
3. PDE3A and PDE3B are frequently highly expressed in GISTs. Modulation of PDE3 activity 
decreased GIST proliferation and promoted apoptosis in vitro. A PDE3 inhibitor, anagrelide, reduced 
cell growth in patient-derived xenograft mouse models. Further testing of anagrelide in clinical trials 
is warranted.
The molecular mechanisms of GIST are still incompletely understood. This study reveals the role and 
function of three new potential molecular factors that may affect the function of the GIST cells and 
the prognosis of GIST patients. Further studies may show whether these proteins are of clinical 
importance, and will hopefully open up new therapy options for GIST patients.
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